The Effects of Recombinant Human Growth Hormone on Patients Undergoing Elective Knee Replacement for Osteoarthritis. by Wright, Juliet Elizabeth.
The effects of recombinant human growth 
hormone on patients undergoing 
elective knee replacement for osteoarthritis.
by
Juliet Elizabeth Wright 
MBBS MRCP
Submitted for the degree of Doctor of Medicine
Postgraduate Medical School 
University of Surrey
October 2005 
© Juliet E Wright 2005
P ro Q u e st N um ber: 27750491
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent on the quality of the copy submitted.
in the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27750491
Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.
Ail Rights Reserved.
This work is protected against unauthorized copying under Title 17, United States Code
Microform Edition © ProQuest LLC.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106 - 1346
Summary
Objective
Interventions to increase lean body mass pre-operatively and prevent or reduce 
postoperative catabolism could be of great benefit in elderly patients with reduced 
lean tissue reserve. This study examined the effects of recombinant human growth 
hormone (GH) treatment on body composition and function in elderly patients 
undergoing elective knee replacement for osteoarthritis.
Method
32 patients (aged 58-78 years) were studied in this double blind placebo controlled 
study. GH or placebo was given for 14 weeks preoperatively (target dose 0.1 
lU/Kg/day) and for 4 weeks post operatively. Serum IGF-1, IGFBP2, IGFBP3, body 
composition, mid-thigh muscle cross-sectional area, muscle strength, 4 minute 
walking distance and quality of life were measured at baseline, one week pre­
operatively, four weeks postoperatively and twelve weeks postoperatively.
Results
Following treatment mean serum IGF-1 was raised significantly compared to baseline 
in the treatment group with a parallel increase in IGFBP3. There were no significant 
changes in IGFBP2. Lean mass increased preoperatively by an average of 2 Kg with 
growth hormone treatment (p<0.05 vs placebo). There was a non-significant increase 
in the mid-thigh muscle cross-sectional area following growth hormone treatment.
This increase in lean body mass was not sufficient to overcome the losses associated 
with postoperative catabolism. Growth hormone showed no significant changes in 
muscle function pre or postoperatively. Four minute walking distance showed a trend 
although statistically non-significant in favour of the treatment group with an 
increase, on average, in the GH group and a reduction, on average, in the Placebo 
group after 14 weeks of treatment and an increase, on average, in both treatment 
groups at study termination. The quality of life analysis shows a beneficial trend in 
the treatment group in keeping with quality of life changes that are seen in growth 
hormone deficient patients. Dose related side effects were seen in many of the patients 
receiving growth hormone.
Conclusion
In patients undergoing total knee replacement for osteoarthritis, pre-operative GH 
treatment results in increased lean body mass. The treatment may have some positive 
effects on aspects of function and quality of life. Treatment with GH was not able to 
offset postoperative catabolic losses or effect physiotherapy milestones or length of 
inpatient stay.
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Chapter 1 
Introduction
Growth Hormone 
Growth hormone history
Although growth properties of pituitary extracts were demonstrated in the 1920's, 
bovine growth hormone was not isolated until 1944 and human growth hormone was 
not isolated until 1956 (Li & Evans, 1944; Li & Papkoff,1956). Pituitary extracts were 
then used for the treatment of growth hormone deficiency in the following year 
(Raben, 1958). During the 1950's growth hormone for clinical use was extracted from 
human pituitary glands obtained at post mortem (Henneman, 1960). At this time there 
was no reliable method for measuring plasma levels of growth hormone. Thus the 
diagnosis of growth hormone deficiency and the indications for the use of growth 
hormone were clinical and empirical. With the advent of radioimmunoassay 
measurement of plasma growth hormone, a powerful diagnostic tool became available 
and this has been widely used since the 1960's. Growth hormone supplies remained 
limited and its clinical use was largely restricted to children with classical growth 
hormone deficiency. In early 1985 the FDA (Food and Drug Administration) in the 
USA received the report of a young adult who had been given pituitary derived 
growth hormone in the late 1960's and early 1970's who subsequently died of a 
progressive neurological disorder characterised by dementia, dysarthria and gait 
disturbance (Underwood et al 1985). Creutzfeldt-Jacob's disease, an uncommon 
cause of dementia and death in older adults was confirmed at post mortem. Two 
additional cases were reported shortly afterwards and pituitary derived growth 
hormone was withdrawn from the market in 1985 (Buchanan et al 1991). 
Fortunately, recombinant derived growth hormone for use in humans was approved 
shortly afterwards. Thus, recombinant DNA technology has created an essentially 
limitless supply of growth hormone for use in humans, resulting in an explosion of 
studies exploring additional potential uses for growth hormone.
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Growth hormone (GH) is essential for normal growth in childhood (Aschner, 1912) 
but also has many direct and indirect effects on metabolism, body composition and 
immunity in adults. The indirect effects are through its stimulation of production of 
insulin-like growth factor (IGF-1), and by interaction with other hormones. GH and 
IGF-1, together with the hypothalamic hormones that control growth hormone 
secretion, are collectively known as the somatotrophic axis.
Growth Hormone Structure
Growth hormone is the most abundant pituitary hormone. It is a single chain protein 
with 191 amino acids and two disulphide bonds (Cooke Ne, 1988). The GH gene is 
located on chromosome 19 (Cooke Ne, 1988). Approximately 75% is secreted as the 
22kD form (Cooke Ne, 1988). The remainder consists of a 20 kD variant produced by 
alternate splicing (De Noto FM, 1981). The three-dimensional structure is a four 
helical bundle topology with two receptor-binding sites (Leung, 1987). GH is secreted 
by the somatotrope cells which are located predominantly in the lateral wings of the 
anterior pituitary (Horvath, 1988). The number and morphological features of these 
cells are remarkably stable throughout life (Horvath, 1988).
Growth Hormone Binding Protein and Growth Hormone Receptor
About half of the circulating GH is tightly bound to a specific, high-affinity GH- 
binding protein (GHBP), which stores and therefore prolongs its half life and may 
modify its actions on target tissues.
The GH-receptor (GHR) is one of a family of transmembrane receptors that include 
most of the interleukin receptors (Kelly et al, 1991). It is characterised by a large 
extracellular domain, a single transmembrane helix and an intracellular domain 
(Leung, 1987).
GHBP is identical with the extracellular domain of the GHR; it can be isolated from 
serum and binds to GH with a similar affinity to that of the full-length receptor 
located on the cell-surface (Baumann, 1990). GHBP levels vary widely between 
individuals, are slightly higher in women, are correlated with body mass, do not vary
15
with age during adulthood, are reduced in fasting or malnutrition, and raised in 
obesity (Baumann and Mercado, 1993).
One GH molecule has two distinct receptor-binding sites. Through the use of 
mutagenesis it has been demonstrated that receptor binding occurs sequentially: GH 
first associates with the high-affinity site of one GHR. This complex binds a second 
receptor through the second site, which results in the intracellular signalling process 
(Ihle, 1995). Expression of GHR has been found in nearly every human tissue. Portal 
insulin stimulates GH receptor production (Sonksen et al 1993). In severe 
malnutrition and in chronic renal failure, GH receptor levels fall, but can be increased 
by exogenous GH (Veldhuis et al, 1991).
Regulation of GH secretion
Secretion of GH is characteristically pulsatile. About two thirds of the daily GH 
secretion occurs at night, especially during slow wave sleep (Holl et al, 1991). 
Sensitive assays have confirmed that there are continuous, albeit very low, levels of 
GH throughout the day and that GH pulses occur with an average frequency of about 
13/day in both sexes, with a dominant, but not strictly periodic, 2 hour rhythmicity 
(Winer et al, 1990). There is very variable inter-individual variation in GH secretion 
in healthy adults.
Two hypothalamic hormones regulate GH secretion: growth hormone releasing 
hormone (GHRH) with a stimulatory action at the transcriptional level (Barinaga, 
1983) and somatostatin (SST) characterised by an inhibitory effect on pituitary GH- 
secretion (Dorflinger, 1983). Both are produced in the hypothalamus, secreted into the 
capillaries of the median eminence and then pass via the portal veins into the pituitary 
gland. GHRH is a 44 amino acid peptide which amplifies all stages of the production 
as well as the release of GH (Vance et al 1985). Somatostatin exists in two molecular 
forms, with 14 and 28 amino acids, the larger being the more active form (Reichlin
1983). Importantly, a decrease in hypothalamic SST secretion initiates GH secretory 
bursts suggesting that somatostatin regulates the timing and amplitude of pulsatile GH 
secretion rather than GH synthesis. Synthetic compounds like Growth-Hormone- 
Releasing-Protein-6 (GHRP), a hexapeptide (Bowers, 1998), and the recently 
discovered natural hormone, Ghrelin (Kojima, 1999), have probably a dual effect: 
increasing GHRH release and inhibiting somatostatin resulting in a potent stimulation
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of GH. They act together with GHRH but via a specific receptor localised at the 
pituitary and hypothalamic level (Kojima, 2001).
GH stimulates IGF-1 (formerly called somatomedin C) production in the liver which 
is the major source of circulating IGF-1 (Clemmons and Van Wyk, 1984). Hepatic 
production of IGF-I decreases pituitary GH release via a negative feedback 
mechanism at the pituitary and hypothalamic level (Cheetham, 1993). In addition, GH 
itself exerts a short loop negative feedback at the hypothalamic level (Berelowitz, 
1981).
Gonadal steroids, particularly estradiol (Ho, 1987), are important modulators of GH 
release. The site of action of these gonadal steroids may be in the periphery (IGF-I 
\ synthesis), the pituitary or hypothalamic level.
Serum GH concentration is reduced in obesity (Rudman et al, 1981; Veldhuis et al 
1991). The amplitude of secretory bursts and the half-life of growth hormone are 
negatively correlated with percentage body fat (Veldhuis et al, 1995), and GH release 
in response to a range of usual stimulatory influences is blunted (Williams et al,
1984).
Numerous substances, some natural, some pharmaceutical, also affect GH secretion. 
These include stimulation by amino acids, particularly tryptophan and arginine, the 
stimulatory affect of which, by inhibiting SST (Alba-Roth et al 1998), is the basis of 
the clinical test of GH secretion ability. Neurotransmitters exert their affects via 
GHRH and/or SST. Acetylcholine acts by inhibition of SST secretion (Krulich, 1979) 
thus enhancing GH release. Catecholamines have both stimulatory and inhibitory 
effects mediated by oc2 and B receptors respectively via GHRH and SST. Fasting 
produces a marked increase of GH release in healthy men and women, with both 
increased peak frequency and amplitude (Hartmann et al 1992). Hypoglycaemia is a 
powerful stimulus for GH secretion (Tandon et al 1965), acting at the hypothalamus 
to reduce SST inhibition of GH release (Cordido et al 1993). Hyperglycaemia reduces 
growth hormone secretion acting via insulin, the effect being blunted in diabetes. 
Patients with Cushings syndrome have reduced GH secretion and, although there may 
be acute GH secretion in response to adrenal glucocorticoids, the longer term effect is 
inhibition (Casanueva et al 1998). High dose cortisol treatment reduces GH levels and 
this contributes to the catabolic effect and muscle wasting. Hypothyroidism is 
associated with reduced GH and IGF-1 levels which are reversed by thyroxine
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(Williams et al 1995). Exercise stimulates growth hormone secretion (Shepherd and 
Sidney 1975), but also produces a direct increase in circulating IGF-1 independently 
of GH (Cappon et al 1994). Thus many factors contribute to the considerable inter­
individual variation in growth hormone secretion
Growth Hormone Action
There are two theories regarding the action of GH: the somatomedin (or IGF-I) 
hypothesis and the GH hypothesis. The somatomedin hypothesis is based on the 
observation that efficient mitotic activity of cartilage is dependent on a combination 
of GH and a serum factor oringinally termed that was subsequently shown to be 
identifcal to IGF-I (Daughaday, 1989; Salmon, 1957). These observations suggest that 
IGF-I is the important mediator of GH action, and the fact that IGF-I exerts a negative 
feedback on pituitary GH release further supports this hypothesis (Berelowitz, 1981). 
Alternatively, direct actions of GH at various sites in humans have been proposed 
supported by studies in isolated organs and tissues (Isaksson, 1985). Importantly, 
locally synthesised IGF-I acting in a paracrine or autocrine fashion can contribute to 
these effects (Isaksson, 1985)
Insulin-Like Growth Factor
Insulin-like Growth Factor-I Structure
Insulin-like growth-factor-I (IGF-I) is a basic peptide of 70 amino acids and shares 
48% sequence homology with human pro-insulin (Rinderknecht, 1978). The 
molecular weight is 5.8 kD (Rinderknecht, 1978) and its gene is located on 
chromosome 12 (Brissenden, 1984). IGF-I has A and B chains like insulin which are 
connected by disulfide bonds (Rinderknecht, 1978). The connecting C-peptide region 
is 12 amino acids long without homology with the C-peptide region of pro-insulin 
(Rinderknecht, 1978). The structural similarity explains the ability of IGF-I to bind to 
insulin receptors and of insulin to associate with IGF-I receptors.
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IGF-I Receptor
Most of the cellular effects of IGF-I are mediated by binding to the IGF-I receptor 
(Massague, 1982). Like the insulin receptor the IGF-I receptor is an aiPz 
heterotetramer. It contains two extracellular a  subunits whereas the two p subunits 
have a short extracellular domain, the hydrophobic transmembrane domain and the 
intracellular tyrosine kinase domain (Massague, 1982). Autophosphorylation on 
tyrosine residues in response to ligand binding occurs in both IGF-I receptors and 
insulin receptors initiating the intracellular signalling pathway (Kato, 1993).
Insulin-Iikc Growth-Factor Binding Proteins (IGFBP)
In contrast to insulin, IGF-I circulates in plasma complexed with a family of specific 
binding proteins (Jones, 1995). To date six binding proteins have been fully 
characterised but recent evidence suggests that there may be as many as 10 binding 
proteins (Baxter, 2000). These binding proteins affect the bioavailability, circulating 
half life and action of the IGFs. Interestingly, the affinity of IGF-I for its binding 
proteins is higher than that of IGF-I receptors implying that binding proteins modulate 
IGF-I binding to its receptor (Oh, 1993). The functions of the IGFBPs are to act as 
transport proteins, to “store” IGF-I within the circulation thereby prolonging the half- 
lives and regulate the metabolic clearance of IGF-I, to provide a means of tissue and 
cell-type-specific localisation, and to modulate interaction with the IGF-I receptor 
(Jones, 1995).
IGFBP3 is produced by the liver and is the most abundant of the IGFBPs in adults, 
accounting for 95% of the total circulating IGFBPs. Approximately 75% of the IGF-I 
circulates as a 150 kD complex that consists of IGF-I, IGFBP-3 and a non-IGF-I 
binding component termed acid labile subunit (ALS) (Jones, 1995). This complex 
does not leave the vascular compartment, and the half-life of IGF-I within this 
complex is prolonged to 12-15h (Jones, 1995). This contrasts with the half-life of free 
IGF-I estimated to be less than 10 minutes (Jones, 1995). Plasma IGFBP-3 
concentrations are positively regulated by GH and, although only transiently, by IGF-
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I administration (Jones, 1995).
IGFBP-1 and 2 as well as IGFBP 4-6 are lower molecular weight binding proteins. 
They have been shown to cross intact endothelial barriers (Jones, 1995) suggesting a 
possible role as an “IGF-I shuttle” to target tissues. Amongst these binding proteins 
IGFBP-1 appears to be the most important factor regulating IGF-I bioavailability. In 
addition to the role as a carrier protein, IGFBP-1 has an important metabolic role as 
evidenced by its hormonal regulation: insulin suppresses and glucocorticoids enhance 
plasma IGFBP-1 concentrations at the transcriptional level (Jones, 1995). 
Furthermore, catabolic states (associated with low insulin levels) result in an increase 
in IGFBP-1 gene expression (Jones, 1995). IGFBP-2 is expressed in multiple tissues 
during development. The highest expression is found in the central nervous system. In 
adults high expression is detected in the central nervous system and reproductive 
tissues. IGFBPs have important roles in cell growth and differentiation as well as 
growth related abnormalities and some types of cancer (Yu H et al, 1999).
Regulation of Insulin-like Growth Factor
GH stimulates IGF-1 production in the liver and this is the major source of circulating 
IGF-1 (Clemmons and Van Wyk, 1984). GH also stimulates IGF-1 production in a 
number of other tissues (D’Ercole et al 1984). This locally produced IGF-1 may act in 
a paracrine or an autocrine manner (Holly and Wass 1989). Hepatic production of 
IGF-I decreases pituitary GH release via a negative feedback mechanism at the 
pituitary and hypothalamic level (Cheetham, 1993).
Given that the circulating IGF-I concentration in healthy adults is approximately 100 
nmol/L and the IGF-I-receptor on most cells is typically approaching saturation at 
IGF-I concentrations of 5 nm/L or lower, it becomes clear that IGFBPs are the most 
important factors regulating IGF-I bioavailability and, therefore, IGF-I action (Baxter, 
2000). The functional consequences of interaction between IGF-I and IGFBP are 
usually an inhibition of IGF-I activity (Baxter, 2000). However, degradation of 
IGFBPs by endoproteases generates IGFBP fragments with low affinity for IGF-I and, 
consequently, increased IGF-I bioavailability (Baxter, 2000). For example IGFBP- 
degrading proteases secreted by breast and prostate cancer have been proposed to act 
as growth stimulators by increasing local IGF-I availability (Baxter, 2000). Similar
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phenomena have been demonstrated in ovarian follicular development, in which IGF- 
I actions are blocked by IGFBP-4 during follicular atresia and restored by the action 
of IGFBP-4 protease (Baxter, 2000). The development of protease-resistant mutants 
has added further support to the importance of proteases in modulating the 
predominately inhibitory role of IGFBPs (Baxter, 2000).
Despite the recent advances, particularly in IGFBP cell physiology, many questions 
regarding the regulation of IGF-I action remain unanswered.
Insulin-like Growth Factor Action
According to the somatomedin model (Daughaday, 1989). GH secretion controls IGF- 
I levels and IGF-I acts directly at the cellular level. In general, the physiological 
effects of IGF-I are either acute or longer-term effects on cell replication and 
differentiation. Numerous different studies using cell cultures have shown that IGF-I 
affects cell cycle progression by stimulating DNA synthesis and cell replication 
(Jones, 1995). Furthermore, cell proliferation and differentiation is enhanced and cell 
apoptosis is inhibited (Jones, 1995). The significant impact of IGF-I on cell 
proliferation and apoptosis and the positive correlation between IGF-I concentrations 
and risk for several cancers, has provoked caution in using IGF-I as a therapeutic tool 
despite the fact that its metabolic actions could be promising in several clinical 
conditions.
Metabolic Effects of Growth Hormone and Insulin-like Growth Factor 
GH and glucose metabolism
GH induced insulin resistance has been confirmed in healthy subjects using the 
euglycaemic and the hyperglycaemic clamp technique (Bratusch-Marrain, 1982; 
Orskov, 1989). Patients with acromegaly exhibit insulin resistance, often associated 
with frank diabetes mellitus in keeping with the findings of GH administration in 
healthy volunteers (Jadresic, 1982). Treatment strategies aiming at controlling GH 
excess in patients with acromegaly (eg. surgery, octreotide result in improvement of 
insulin resistance and glucose tolerance (Wass, 1980).
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Abdominal obesity is associated with insulin resistance and blunted GH secretion 
(Johannsson, 1997). GH therapy results in a decrease in body fat, particularly visceral 
fat mass, but is associated with an increase in insulin resistance after 6 weeks 
followed by a decrease in insulin resistance after 9 months, (Johannsson, 1997).
GH and Protein metabolism
Studies in hypophysectomized animals have demonstrated that hypophysectomy is 
associated with loss of body protein, which is restored by growth hormone 
administration. In early studies, it was demonstrated using amino acid tracers that GH 
stimulated the uptake of amino acids into rat diaphragm (Kostyo, 1968). GH also 
stimulated the incorporation of labelled glycine into protein; this effect was 
independent of amino acid uptake (Kostyo, 1968). GH has also shown to increase the 
number and activity of ribosomes in rat muscle and to increase RNA polymerase 
suggesting that the hormone may control synthesis at the level of translation (Florini 
& Breuer 1996).
In a randomised double-blind placebo-controlled trial of the effect of GH replacement 
on protein metabolism involving 18 GH-deficient adults, protein synthesis was 
significantly increased after 2 months (24%), with no alteration in protein degradation 
(Russell-Jones, 1993).
The major alterations in body composition occur within 1-2 months of 
commencement of GH therapy (Carroll, 1998), and it is likely that any significant 
alteration in protein metabolism would occur over this period. This may account for 
the results in the studies of protein metabolism, which have demonstrated an increase 
in protein synthesis up to 2 months after commencement of GH, but little alteration 
above baseline after 6 months therapy.
GH and Fat Metabolism
In 1965 Swislocki & Szego, showed in controlled studies of hypophysectomized 
animals, that, compared with placebo, GH had the effect of increasing free fatty acid 
(FFA) concentrations in the blood stream, but this was always preceded by a small but 
significant transient reduction in FFA concentrations in blood, and to this day, has not
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been fully explained. They went on to show that the percentage of water in 
epididymal fat pads increased in a manner similar to that of FFA concentrations in the 
blood stream. This observation was explained on the basis of a lipolytic effect of IGF- 
1 in adipose tissue, in the same way that IGF-1 in large doses produces initial 
hypoglycaemia, and thus the GH was truly lipolytic, by inducing lipolysis of 
triglycerides to liberate FFAs (Swislocki & Szego 1965). The change in FFA 
metabolism undoubtedly has an influence on lipoprotein and lipid metabolism. Using 
stable isotope turnover studies, Christ et al, 1999 were able to show that GH 
replacement caused a slight increase in the production of very low density 
lipoproteins, but this was far outweighed by a much larger increase in clearance rate. 
The net effect of these changes is a decrease in circulating concentrations of the 
lipoproteins and lipids, plus a dramatic decrease in the residence time of the 
lipoprotein particles within the circulation, thus preventing lipoprotein and lipid 
oxidation and resulting in a less atherogenic lipid profile.
Although most of the anabolic effects of GH are mediated by IGF-I some of the 
metabolic actions of these hormones are contradictory, in particular with regard to 
glucose and fat metabolism.
IGF-1 and Glucose metabolism
In the postprandial setting, IGF-I infusion (7-14 pg/kg/h) results in a significant 
decrease in the insuliniglucose ratio during a glucose tolerance test confirming an 
increase in insulin sensitivity (Zenobi, 1992). The mechanism of this phenomenon is 
unknown but may be due to indirect or direct effects. Indirect effects could be due to 
an IGF-I-mediated suppression of insulin leading to up-regulation of insulin receptors 
and suppression of GH secretion, with resultant loss of GH-mediated insulin 
resistance (Froesch, 1996).
IGF-I and Protein metabolism
Several studies have been performed investigating the effect of an acute infusion of 
IGF-I on protein metabolism in healthy subjects. Consistently, an insulin-like effect
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with a reduction in proteolysis without affecting protein synthesis has been observed 
(Boulware, 1994, Mauras, 1992). These results have been surprising, as IGF-I has 
been shown to mediate some of the anabolic actions of GH and GH treatment has 
been shown to stimulate protein synthesis in humans (Russell-Jones, 1993). However, 
these studies were performed on fasted subjects with unphysiologically low amino 
acids levels as substrate for protein synthesis. By supplying sufficient substrate using 
an amino acid clamp technique combined with stable isotope technique, Russell Jones 
et al (1994) have shown that IGF-I increases protein synthesis whereas insulin inhibits 
protein degradation. It is, therefore, conceivable that the metabolic actions of IGF-I 
depend upon substrate availability, with IGF-I reducing proteolysis during periods of 
low availability (fasting) and stimulating protein synthesis during periods of adequate 
substrate availability (postprandial).
IGF-1 and Fat Metabolism
A single intravenous injection of lOOpg/kg IGF-I in healthy volunteers reduces FFA 
concentrations. However, the anti-lipolytic effect of IGF-I is less potent than that of 
insulin; the effect is transient, and affects FFA levels only immediately after the IGF-I 
injection (Guler, 1987).
However, continuous intravenous infusion of IGF-I results in a sustained decrease in 
FFA levels (Boulware, 1992, Mauras, 1992). These investigators administered 
supraphysiological doses of IGF-I, and it is conceivable that the anti-lipolytic action is 
due to cross-reactivity with the insulin receptor. Alternatively, indirect mechanisms 
(eg. decrease in GH and insulin secretion augmenting insulin sensitivity) may 
contribute these findings.
Adult Growth Hormone Deficiency
Growth hormone deficiency in the human adult most commonly results from pituitary 
or peri-pituitary tumours and/or their treatment. These tumours are mostly benign; 
pituitary adenoma is the most common. Childhood onset GH deficiency is most 
commonly idiopathic and is not necessarily associated with other pituitary hormone
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deficiencies. In addition to revolutionising the treatment of GH deficiency in children, 
the availability of recombinant growth hormone has led to intensive investigation of 
the effects of growth hormone in health and disease and, in particular in adult GH 
deficiency.
The first placebo-controlled studies of GH replacement in GH deficient adults were 
reported in 1989 (Salomon, 1989, Jorgensen , 1989). These and subsequent studies 
have led to the recognition of a specific clinical syndrome in adults with longstanding 
growth hormone deficiency. Consistently it has been demonstrated that adults with 
growth hormone deficiency are both physically and psychologically less healthy than 
their age matched peers, and that growth hormone replacement results in substantial 
and sustained benefits.
Clinical manifestations of adult growth hormone deficiency and the effects of 
growth hormone replacement.
The clinical and laboratory features of GH deficiency in adults are shown in the table 
below.
Table 1. The clinical features of GH deficiency in adults
Symptoms: Abnormal body composition
reduced lean body mass 
increased abdominal adiposity 
Reduced strength and exercise capacity 
Impaired psychological well-being 
reduced vitality and energy 
depressed mood 
emotional lability 
impaired self control 
anxiety
increased social isolation
Signs: Overweight with predominately central adiposity
Thin, dry skin
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Cool peripheries 
Reduced muscle strength 
Reduction in exercise performance 
Depressed affect 
Labile emotions
Investigations: Stimulated GH level below 3mcg/L
Low or low-normal IGF-1
Elevated serum lipids, especially LDL cholesterol
Reduced lean body/increased fat mass
Reduced bone mineral density
Body Composition
A reduction in lean body mass (LBM) and an increase in fat mass are important 
features of adult growth hormone deficiency. Studies have demonstrated a mean 
reduction in LBM of 7-8%, corresponding to approximately 4 kg lean tissue 
(Bengtsson BA, 1993, Chong PKK, 1994). Salomon et al, 1989, were the first to 
demonstrate that fat mass was higher by a mean of 7% in GH-deficient patients 
compared with predicted values based on age, sex and height. Using a wide range of 
measurement techniques this has been confirmed by a number of other investigators. 
Body fat distribution has been assessed in a number of studies by waist/hip ratio, skin 
fold thickness, (Salomon et al, 1989), CT scan (Bengtsson BA, 1993) and MRI (Snel 
YE, 1995), with consistent results. The excess fat accumulates in a central 
distribution, mostly in the visceral component. In epidemiological studies, this 
abdominal distribution has been associated with an increase risk of mortality and 
morbidity firom cardiovascular disease. Studies employing a radioisotope dilution 
technique and bio impedance measurements indicate that total body water is reduced 
in adult growth hormone deficiency (Rosen T, 1993). This is mainly due to a 
reduction in extracellular water, due to a reduction in plasma volume (Moller,1996) 
and in total blood volume (Christ ER, 1997).
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In all reported studies investigating the effects of GH treatment on body composition, 
an increase was recorded in lean body mass varying from 2 to 5.5kg after 6 months 
GH replacement (Jorgensen, 1989). Similar findings have been reported from studies 
in both adult-onset and childhood-onset growth hormone deficiency (Attanasio A, 
1997). GH replacement results in an increase in total body water particular in 
extracellular water (Christ, 1997). GH therapy resulted in a 400ml increase in total 
blood volume after 3 months treatment (Christ, 1997)
Bone mineral density and Bone Metabolism
Studies of bone mineral density have consistently shown reduced bone mass at a 
variety of skeletal sites in patients with gro’wth hormone deficiency (O’Halloran D, 
1993).GH replacement in the short term (up to 6 months) has been shown to have 
very little effect on HMD and in some subjects to result in a decrease in HMD (Baum, 
1996). The evidence suggests that the effect of GH is biphasic; following initial bone 
resorption, stimulation of bone formation leads to a net gain in bone mass after 12-24 
months of treatment.
Cardiovascular System
Adults with hypopituitarism have a greater than twofold increase in mortality from 
cardiovascular disease. (Rosen, 1990). It is considered that GH deficiency (GHD) 
contributes significantly to this, and that GHD predisposes to premature 
atherosclerosis. Studies investigating cardiac performance and dimensions have 
shown reduced left ventricular mass, impaired systolic function in GHD patients 
compared with healthy controls. Treatment with GH for 6 months normalized these 
findings and 6 months after treatment was stopped cardiac function returned to 
baseline, (Amato G, 1993; Colao A, 1999). There is evidence that changes in left 
ventricular mass and cardiac output following 6 months treatment may be sustained 
for 3 years (Sartorio A, 1997).
27
Muscle Strength and Exercise Performance
Reduced lean body mass in GHD results in a moderate reduction in muscle strength. 
Studies have demonstrated a reduced quadriceps force in adults with GHD compared 
to age-matched normal controls (Cuneo, 1990), with an increase in isometric limb 
girdle force after six months of growth hormone treatment (Cuneo, 1991).
Treatment with GH (for at least 12 months) results in an increase in quadriceps force, 
with a ftirther increase and normalization after 3 years (Jorgensen J, 1991).
Exercise capacity is dependent on muscle strength and cardiovascular performance. 
Studies observing oxygen uptake have demonstrated a 72-82% reduction in GHD 
compared to controls (Cuneo, 1990). Following 6 months GH treatment oxygen 
uptake reached predicted values (Cuneo, 1991). This increase in performance is 
largely attributable to increased muscle mass (Rutherford, 1995).
The effects of growth hormone on body composition and muscle strength have been 
investigated using DEXA (dual energy X-ray absorptiometry) and total body 
potassium and total body water. After 6 months treatment, modest changes were seen 
in strength of knee extension and arm flexion. These changes correlated poorly with 
the changes seen in body composition. However GH treatment had not normalized 
these values leading to the authors’ conclusion that inappropriate GH treatment might 
have accounted for the anomaly between the increase in strength without alteration in 
LBM (Bell W, 1999).
There is evidence that erythropoiesis is impaired in adult growth hormone deficiency. 
GH stimulates erythropoiesis and this may contribute to the increased exercise 
performance seen in GH therapy (Christ, 1997).
Reduced whole body resting energy expenditure (REE) has been shown in adults vrith 
GHD (Snel Y, 1995), and this is reversed by GH treatment (Saloman F, 1989). Much 
of this is attributed to the increase in LBM. However when the increase in REE is 
expressed per LBM these rises are still significant indicating that there is a direct 
increase in cellular metabolism.
GH treatment increases circulating triiodothyronine levels. GH is a physiological 
regulator of thyroid function and in particular the peripheral monodeiodination of 
thyroxine.
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Protein and Carbohydrate Metabolism
There have been a few studies that have assessed protein metabolism in GHD using 
stable isotope studies. These have shown reduced protein flux and synthesis in adults 
with GHD compared with healthy matched controls. GH treatment resulted in 
considerable increases in protein synthesis in the short term (1-2 months), and a return 
to baseline rates after 6 months (Russell-Jones D, 1993).
The increased central adiposity of adult GHD is associated with hyperinsulinaemia 
(Saloman F, 1989). GH replacement has been shown to increase insulin resistance still 
further over a period of 6 weeks therapy, but although hyperinsulinaemia persists 
carbohydrate metabolism returns to baseline after 3 months treatment (Fowelin, 
1993).
Psychological Well-being and Quality of Life
Decreased psychological well-being has been reported in hypopituitary adults despite 
replacement of all hormone deficiencies with the exception of GH (Stabler B, 1992). 
In most studies GH replacement results in significant improvements in quality of life 
and psychological well-being in patients with GHD ( McGauley G, 1989, ). Evidence 
suggests that those with the greatest psychological morbidity benefit the most from 
GH treatment (Murray R, 1999).
Reported adverse effects of growth hormone replacement
Genetically engineered recombinant GH has an identical structure to natural human 
GH and is not associated with the risks attributable to human extracted or animal 
derived products.
Most adverse effects associated with GH replacement in GHD are related to the anti- 
naturietic effect of GH. Early dosage regimens in adults were based on paediatric 
practice and produced IGF-1 levels above the normal limit resulting in adverse events. 
More recent studies have shown that lower doses that are better tolerated and can be 
considered more physiological. Patients most at risk are older, more obese, and with a
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greater GH response on provocative testing and the largest IGF-1 rise on GH 
treatment. The most common side effects are weight gain, dependent oedema, and 
carpal tunnel compression. These usually occur within days or weeks of initiating 
treatment. All symptoms disappear with dose reduction or frequently disappear 
without any action.
There have been isolated reports of cerebral side effects resulting from GH 
replacement; these include encephalocele, tinnitus and benign intracranial 
hypertension. There have been concern regarding the effects of GH treatment on 
tumour development and recurrence. Reassuringly, data from long term studies in 
children with both solid tumours and haematological malignancies suggest that there 
is no increased risk of recurrence associated with growth hormone therapy.
Ageing
Ageing and Growth Hormone Status
The amount of growth hormone released by the anterior pituitary is reduced in healthy 
elderly compared with young healthy adults (Finkelstein, 1972, Dieguez 1988). Early 
studies suggested that GH secretion had ceased by the seventh decade of life 
(Finkelstein, 1972). However the sensitivity of the assays used at this time was poor. 
Modem assays are much improved, and their use in studies to assess physiological 
GH secretion has shown that GH secretion occurs throughout adult life. The amount 
of GH secreted does however decline with advancing age, at a rate of about 14% per 
decade of life (Iranmanesh, 1991).
It is interesting that the amount of GH present in the anterior pituitary does not change 
with increasing age, and that an appropriate stimulus in an elderly adult can produce a 
GH pulse similar to that seen in a younger adult (Ghigo, 1996; Toogood, 1998). Thus 
it considered that the age related decline in GH secretion is attributable to changes in 
the pattern of secretion of GHRH and SST.
In the elderly the frequency of the GH pulses is the same as in young adults; however 
the amplitude of the pulses is decreased (van Coevorden, 1991), suggesting that 
GHRH activity is reduced. The administration of GHRH by twice daily injections or
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by continuous infusion in elderly subjects for two weeks increased spontaneous GH 
secretion and caused a rise in serum IGF-1 concentrations to levels seen in younger 
adults (Corpas, 1992; 1993b).
Arginine is a GH secretagogue that is used in the diagnosis of GH deficiency in adults 
and children. Arginine inhibits the secretion of somatostatin from the hypothalamus 
and induces a pulse of GH to be released. The GH response to arginine in healthy 
elderly adults is not significantly reduced compared with the GH response seen in 
younger adults (Toogood, 1998). When arginine and GHRH are administered 
together, a pronounced release of GH occurs which is not affected by the age of the 
subject (Ghigo, 1996). These observations suggest that the pool of GH available for 
release is not diminished in the elderly; GHRH activity is reduced in the elderly, but 
the increase in the SST tone is primarily responsible for the age related decline in GH 
secretion; which may be explained by diminished cholinergic tone. Pyridostigmine 
increases cholinergic tone and its administration to older patients results in enhanced 
basal and GHRH induced GH secretion (Giusti, 1991). However, a recent study 
(Soule SG, 2001) provides conflicting evidence to this theory. In this study gro’svth 
hormone secretion in 8 young and 8 elderly men was stimulated on separate occasions 
by means of: 1) intravenous bolus of GHRH, 2) intravenous bolus of GHRH after pre­
treatment with oral dosing of atenolol to inhibit somatostatin secretion, 3) 
bromocriptine alone to increase endogenous GHRH and/or inhibit somatostatin, 4) 
atenolol plus bromocriptine and 5) intravenous bolus of GHRH after pre-treatment 
with bromocriptine. The elderly had a significantly lower peak and area under the 
curve (AUG) GH response to intravenous GHRH when compared with 8 young men. 
Pre-treatment with atenolol before GHRH administration produced no significant 
increase in peak and AUG GH response in both groups. Bromocriptine alone did not 
cause a significant rise in GH concentration in either elderly or young subjects. When 
atenolol was administered before bromocriptine, both groups responded, but the 
elderly subjects had a significantly greater peak and AUG response. Bromocriptine 
given before GHRH failed to potentiate GHRH action on GH release in either group. 
Of 5 elderly men who underwent further evaluation of GH secretory ability, 2 had GH 
levels > lOng/ml, either basally or after intravenous GHRH. The remaining 3 had 
initially impaired GH response to bolus iv GHRH; following 100 micrograms GHRH 
subcutaneously twice daily for up to 2 weeks the GH responses to intravenous bolus 
GHRH were reassessed. One patient exhibited a normal response after 1 week of
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GHRH treatment, another had a near normal response after 2 weeks whilst the third 
still had an impaired response by the end of the second week of treatment. This study 
concluded that the restoration of endogenous GH secretion in these elderly patients by 
means of GHRH priming, and the failure of manipulation of somatostatinergic tone to 
restore a normal GH response to GHRH suggests that somatotroph atrophy due to a 
reduction in endogenous GHRH secretion is the principal cause of the diminished GH 
secretion with ageing.
Circulating GHBP levels are reduced in both sexes after the age of 60 years. This may 
represent an independent age-related reduction in the number of peripheral, mainly 
hepatic, GH cell membrane receptors or may reflect the reduced GH secretion rate 
itself (Corpas, 1993a).
The discovery of the natural hormone ghrelin (Kojima, 1999), has given further 
insight into the mechanisms involved in the control of growth hormone secretion. Its 
receptor is found in the hypothalamus and in the anterior pituitary, suggesting that it 
regulates GHRH and somatostatin release from the hypothalamus and directly 
stimulates the somatotroph. Administration to elderly patients of the synthetic 
peptide hexarelin, a ghrelin analogue and a known GH secretagogue, results in a GH 
response in excess of that observed following GHRH (Arvat, 1994). The significance 
of these findings in the decline of GH secretion with increasing age remains to be 
seen.
Ageing Insulin-like Growth Factor I and its Binding Proteins
The serum concentrations of IGF-1 and IGFBP-3 fall gradually with increasing age 
(Landin-Wilhelmsen, 1994; Ghigo, 1996). This is likely to reflect the age-related 
decline in growth hormone secretion, therefore serum IGF-1 and IGFBP-3 
measurement must be evaluated in the context of age-specific normal-range data. In 
adults over 60 years, although serum IGF-1 concentrations are significantly lower in 
growth hormone deficient subjects compared with controls, the overlap between the 
two groups is significant (Toogood, 1998). Only 17% of growth hormone deficient 
subjects in this study had an IGF-1 concentration below the age-specific normal 
range.
The serum concentration of IGFBP-3 also falls with increasing age but to a lesser
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degree than IGF-1 and GH secretion (Donahue, 1990; Corpas, 1992b). IGFBP3 
concentrations in the elderly with pituitary disease are significantly lower than age 
specific normal data; however 96% of the patient values fall into the normal range 
(Toogood, 1998).
The reason for the considerable overlap of IGF-1 and IGFBP-3 between patients and 
controls is uncertain, and it is suggested that with increasing age GH becomes less of 
an important factor in the determination of the circulating IGF-1 concentration and 
other factors such as nutrition and chronic disease may be of greater importance in the 
regulation of IGF-1 and IGFBP-3 by the liver (Toogood, 1998).
Change in body composition with ageing
As previously stated GH deficiency in young adults results in adverse changes in 
body composition with a reduction in lean mass and an increase in fat mass. This 
increase in fat mass is noted to have a central distribution (Weaver, 1995).
Ageing is associated with very similar changes in body composition and fat 
distribution (Forbes, 1970). Computed tomography has shown a reduction in 
subcutaneous fat mass in the upper leg and a shift of abdominal fat from the 
subcutaneous region to the intra-abdominal cavity. (Borkan, 1983)
Muscle mass falls by 1-1.5% per year from about the age of 40 years onwards 
(Young, 1998). By the eighth decade elderly individuals have lost 50% of the lean 
tissue they possessed as young adults (Forbes, 1970).
In healthy men and women aged 65-89 years strength falls by 1-2% year but power 
falls even more, 3.5% per year (Skelton, 1994). Among apparently healthy older 
people, an increased mortality rate is associated with lower body mass indices (Burr, 
1982), although it has been suggested from subsequent studies that this explained by a 
poorer outcome from acute illness (Lehmann, 1996).
This reduction in lean mass that occurs in normal ageing is accompanied by an 
increase in fat mass and many other changes similar to those seen in growth hormone 
deficient adults such as reduced muscle strength and exercise capacity, reduced bone 
mineral content and bone mass (Rudman, 1981; Rudman, 1985). In growth hormone 
deficient young adults these features can be reversed by GH therapy (Jorgensen, 
1989; Saloman 1989; Cuneo 1991a,b; Binnerts, 1992). This has then led to the
33
suggestion that the changes seen in ageing may be caused by the decline in the 
somatotrophic axis (Rudman, 1981; Rudman, 1985). Within the elderly population 
however there has been no correlation between measures of body composition and 
serum IGF-1 levels. Correlates of IGF-1 levels were investigated in the group of 
subjects reported from the Framingham heart study (Harris, 1997). IGF-1 levels fell 
with age but were not associated with low lean body mass, increased fat mass, 
functional status or grip strength. In a cross sectional Swedish study of 80 year olds, 
serum IGF-I was not associated with body composition measured by impedance 
analysis (Erfurth, 1997). A study comparing 49 healthy community living men aged 
58-85 years with 49 nursing-home residents aged 58-95 years demonstrated lower 
and significantly different levels of both serum IGF-I and testosterone, and of total 
body bone mineral capacity and lean body massiheight ratio in the nursing home 
residents (Rudman, 1994). Multiple regression analyses were used to investigate the 
possible factors determining body composition. In the community sample, bone 
mineral density at several sites and total body bone mineral content were significantly 
related to serum total testosterone but not to IGF-1, age or habitual physical activity. 
Age was the only predictor of lean body mass. In the nursing home residents, bone 
mineral density was related to age and degree of immobility but not to IGF-I or 
testosterone. Once again age was the only independent predictor of lean body mass. 
Whilst highlighting the lack of association between IGF-1 and body composition in 
the elderly, this study also raises the possibility that different subgroups based on 
fiailty will be differentially dependent on various anabolic hormonal influences.
Growth Hormone Treatment of Normal Older Adults
GH treatment of elderly rats has been shown to restore the rate of protein synthesis to 
that seen in young animals (Sonntag, 1985). In the first randomized controlled trial of 
recombinant growth hormone (rhGH) supplementation in humans using three times a 
week subcutaneous injections, equivalent to a daily dose of 13mcg/Kg body weight 
per day over 6 months, 21 healthy older men aged 61-81 years were selected on the 
basis of circulating IGF-1 levels in the lower third for their age and therefore deficient 
by young adult standards. The IGF-1 levels were restored to ‘normal’ and clinically 
relevant effects were seen in the 12 men receiving active treatment (Rudman, 1990). 
Lean body mass rose by 8.8% and lumbar vertebral density by 1.6%. The magnitude
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of the changes produced was equivalent to a reversal of the age-related changes by 
10-20 years. The same group studied the effects of longer term treatment over 12 
months, in a group with similar initial characteristics, including an IGF-1 level of less 
than 0.351 I/m l (Cohn, 1993). Only 18 Of 62 subjects completed 12 months of 
treatment without experiencing one or more of the three common side effects, carpal 
tunnel syndrome, gynaecomastia and hyperglycaemia. There was a clear dosage 
effect, with those receiving treatment which produced an IGF-1 level between 0.5 and 
l.OU/ml having a greater gain in lean body mass and fewer side effects than those 
with a higher IGF-1. Another clinical trial showed a similar pattern and rate of side 
effects and led to the withdrawal with in a few months of six of the twelve healthy 
older men aged 63-76 years receiving daily rhGH injections at a similar net dose 
12.5mcg/Kg per day (Yarasheski, 1993). Papadakis and colleagues reported that a 
cohort of healthy, active men older than 70 years of age with low insulin-like growth 
factor 1 (IGF-1) levels had increased lean body mass (4.3%) and decreased fat mass 
after receiving human growth hormone for 6 months, but disappointingly they found 
no evidence of significant functional improvement, as measured by muscle strength 
and physical endurance (Papadakis, 1996).
Growth Hormone Treatment of Patients Without Growth Hormone Deficiency
There are a variety of studies that have explored the potential benefits of the anabolic 
properties of rhGH in patients without GH deficiency. Ten malnourished elderly 
patients aged 64-99 years with body weight 20% or more below average were given 
rhGH as part of a placebo controlled study, (Kaiser, 1991). Treatment produced a rise 
in circulating IGF-1 and weight gain of 2.2Kg in contrast to a weight loss in the 
control group. There was a significant association between IGF-1 level and weight 
gain. A significant increase in nitrogen retention occurred, suggesting that the weight 
gain was at least partly due to lean tissue. In critical illness such as follow traumatic 
injury, bums, surgery, starvation and infection, GH levels rise whilst IGF-1 levels fall 
and there appears to be an acquired resistance to the anabolic actions of GH, (Ross, 
1991). In such catabolic situations, amino acids are mobilized from skeletal muscle 
and converted to acute-phase proteins and glucose, with nitrogen released
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concomitantly and excreted in urine as urea. In major injury, protein losses continue 
and result in protein malnutrion with poor wound healing and increases susceptibility 
to infection. In patients undergoing major gastrointestinal surgery and receiving 
parenteral nutrition rhGH administration caused significant rises in serum IGF-1, 
transferrin, albumin and total proteins and also caused a positive nitrogen balance 
from 24 hours (Vara-Thorbeck, 1992). Although similar results have been obtained 
with bums patients provided there was adequate protein and calorie intake, several 
studies have shown less or no benefit in severely stressed or immobile patients 
(Behrman, 1995).Two multi centre placebo-controlled studies together involving over 
500 patients assessed the administration of GH in pharmacological doses to critically 
ill patients, commencing 5-7 days after admission to the intensive care unit and 
recorded a doubling of the mortality rate (Takala, 1999). Most of the deaths occurred 
during the first 10 days of GH treatment and were attributable to multi-organ failure 
and sepsis. Various mechanisms have been proposed including GH induced 
alterations in immuno-regulation, amino acid mobilization, insulin insensitivity and 
acid-base homeostasis but the increased mortality remains unexplained. rhGH has 
also been used with potentially beneficial side effects on older adults in a number of 
clinical situations. Patients aged 53-92 years on long term dialysis gained significant 
increases in lean body mass during 6 months treatment with 28mcg/Kg per day of 
rhGH as part of a randomized controlled trial (Ahlen, 1997). Patients awaiting 
elective hip replacement received 3 months treatment with approximately 13mcg/kg 
per day of rhGH which then continued at double dose for 1 month post operatively. In 
comparison to the placebo group, those receiving treatment preserved their muscle 
mass despite immobility and surgery and this was accompanied by a trend towards a 
favourable effect of growth hormone on strength in the majority of muscles tested, but 
this was significant only for the abductors of the non-operated hip (p<0.02), where 
there was a 7% increase in strength over the whole study compared with a 25% 
decrease in the placebo group. Four minute walking distance improved post- 
operatively by a mean 26.9 metres in the GH group compared with a 19.5 metres 
reduction in the placebo group (p<0.05). Dose related side effects were seen in the 
majority of patients receiving GH. In another study frail older women who had 
sustained hip fractures received 25 or 50 mcg/Kg per day of rhGH postoperatively 
This produced significant IGF-1 responses but those who were most frail pre- 
operatively responded least, some not producing a rise in IGF-1 at all (Yeo, 1996).
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The trial was not designed to demonstrate clinical benefit but the IGF-1 response 
suggests that there may be clinical benefit for some.
Osteoarthritis
Osteoarthritis is a predominantly non-inflammatory abnormality of the synovial joints 
which is characterised by cartilage loss and an accompanying bone response. It occurs 
most commonly in the hands, knees, spine and hips. The symptoms include joint pain, 
stiffiiess, limitation of movement and swelling. Osteoarthritis, like rheumatoid 
arthritis, is more common in women than men and, overall, affects 2.5 per cent of the 
population. This percentage increases with advancing age such that osteoarthritis is 
the most common chronic joint condition in individuals aged over 65, where it affects 
approximately 12 per cent of the population (Watson, 1997). For this reason, 
osteoarthritis is the single most important rheumatological cause of disability and it 
poses a significant challenge to health care.
Pathogenesis
The specific aetiological factors are unknown, but a number of genetic, patient 
specific and environmental risk factors have been implicated in the development of 
osteoarthritis. Although an inherited defect in type II collagen metabolism is 
described in families with premature onset polyarticular osteoarthritis, this is rare, the 
genetics of common osteoarthritis still require further evaluation. 
Patient specific factors include obesity, female gender and increasing age. 
Environmental factors include abnormal joint loading during occupations involving 
repetitive use of joints over prolonged periods (Watson, 1997).
Clinical presentation
The most frequent presenting feature of osteoarthritis is pain which is worsened by 
movement, eased by rest and tending to be worse at the end of the day. Morning 
stiffness is also common; unlike that experienced by rheumatoid arthritis sufferers, 
this usually lasts less than 30 minutes. Patients may also complain of crepitus in the
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joints, which is related to movement (Cicuttini F, 1998). 
Swelling of osteoarthritic joints may be caused by synovitis with effusion or 
osteophyte formation at the joint margins. The bony enlargement of osteophyte 
formation may also give rise to visible joint deformity. 
In advanced osteoarthritis, the articular cartilage is lost, the subchondral bone 
collapses and secondary osteophyte formation fails to support the joint. The result is a 
deformed, poorly functioning, painful joint which is unstable in some patients 
(Cicuttini F, 1998). Loss of function of the joint may be caused by pain, swelling, 
deformity or a combination of these factors. In addition to these physical problems, 
anxiety and depression are also commonly associated with osteoarthritis. Their 
severity tends to be related to the degree of pain experienced by the patient. 
Osteoarthritis most commonly affects the knees, hands (the first carpometacarpal, 
distal and proximal interphalangeal joints) and the lumbar and cervical spine. The hip 
is less commonly affected and the least common sites are the ankle, wrist, elbow, 
shoulder and the metacarpophalangeal joints of the hand. 
The pattern of joints involved varies between the sexes. Men suffer more hip disease. 
Women experience more severe and polyarticular disease (Cicuttini F, 1998). The 
degree of disability also depends on the site involved. For example, pain and 
deformity at weight-bearing joints, such as the hip or knee, may immobilise the 
patient, whereas similar changes in the interphalangeal joints of the hand cause less 
functional impairment (Cicuttini F, 1998).
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Figure 1: Cross Sectional Diagram of the knee showing changes found with 
osteoarthritis
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Figure 2: X-ray showing typical changes in severe osteoarthritis
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Management
The aims of osteoarthritis management are primarily to reduce pain, but also to 
optimise mobility, avoid or minimise joint deformity and to educate the patient about 
their disease. The therapeutic options available to realise these goals are limited. Drug 
therapy consists of simple analgesics, topical or oral non-steroidal anti-inflammatory 
agents and local corticosteroid injections. These can be combined with non-drug 
measures such as weight reduction in obese patients, physiotherapy and/or surgery. 
Successful management depends on a "total patient" approach in which the following 
factors are considered:
Pain severity
Functional disability
Patient expectations
Anxiety or depression
Synovitis
Joint instability
Local and general condition of the muscle surrounding the affected joint
Health Economics
It is estimated that at least 4.4 million people in the UK have X-ray evidence of 
moderate to severe OA of their hands; 550,000 have moderate to severe OA of the 
knees and 210,000 have moderate to severe OA of the hips.
The costs to the nation of arthritis are significant. 206 million working days were lost 
in the UK in 1999-2000 - equivalent to a loss of production of £18 billion. The 
estimated direct cost to health and social services was £5.5 billion. The cost of 
prescription costs alone added up to £341 million. Hip and knee replacements cost 
£405 million.(Arthritis Research Campaign, 2002).
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Total Knee Replacement
In 1860, to relieve the pain of roughened, osteoarthritic joint surfaces rubbing on one 
another it was suggested that a variety of materials could be interposed, including pig 
bladder. By 1940, a metallic femoral surface was inserted in the USA and in the late 
1950’s an acrylic upper tibial spacer was also tried.
By the 1960’s and early 1970’s a combination of metal and plastics were inserted with 
bone cement and in parallel with these designs, inter-linked "hinged" prostheses were 
also developed. This was the beginning of Total Knee Arthroplasty Surgery (TKA). 
Improvements in surgical materials and techniques since then have greatly increased 
its effectiveness.
Indications for knee replacement surgery have expanded during the last decade. 
During the 1970s and 1980s, knee replacement surgery was performed mainly for 
pain, disability or deformity. The expected benefits from the operation were reduced 
pain, limb realignment and functional improvement. However, pain was the primary 
reason for knee replacement surgery. As we enter a new century, frinction is a primary 
reason for knee replacement surgery.
Joint implant manufacturers, orthopaedic surgeons and scientists continually strive to 
improve the durability of these devices. Current scientific advances in metallurgy 
have resulted in the use of titanium and cobalt-chrome alloys, which are used for 
femoral and tibial implants, and a low friction plastic component, made of ultra-high 
molecular weight polyethylene polymer, acts as a spacer and articulating surface 
between two metal components.
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Figure 3: Diagram showing Johnson and Johnson FFC Sigma Knee Implants
Johnson & Johnson PFC Sigma knee implants
I
The operation normally takes 1 - 2 hours with most patients being in hospital for 
approximately 10 days.
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Complications
The overall success rate of a TKA is 95% (G J Chamley, 2001).The average life span 
of knee replacements is about a decade.Risks associated with the surgery itself are 
infections at a rate of 1-2% (G J Chamley, 2001). Wound healing can also 
occasionally be delayed with such a complication.Thrombo-embolism is also reported 
in particular in those patients who smoke.
Rationale for study
Patients awaiting total knee replacement for osteoarthritis suffer with a great deal of 
pain and lack of movement at the joint leading to immobility. Reduced muscle mass, 
predominately of the lower limb is a common finding in these patients. The thigh 
muscles especially the quadriceps are especially susceptible to wasting away rapidly 
with immobility and lack of use. It is possible that if pre-operative muscle mass could 
be improved then patients may have a greater chance of a successful operation, a 
shorter stay in hospital and a lower morbidity. The conventional methods that exist to 
increase quadriceps muscle mass by exercise and physiotherapy are very difficult in 
patients with either limited movement or pain at the knee joint.
In recent years there has been particular interest in the role played by the GH/IGF-1 
axis in age-related changes in body composition (Rudman, 1985). Growth hormone 
has a unique physiological role of promoting growth and positive nitrogen balance. In 
normal individuals, growth hormone facilitates intracellular amino acid transport, 
increases protein synthesis and promotes fat mobilisation. The anabolic effects of 
growth hormone are now well established in children with short stature and in adults 
with growth hormone deficiency (Saloman, 1989).
Results of a recent study investigating the effect of growth hormone treatment prior to 
elective hip replacement in elderly patients has shown that a daily dose of 0.04IU/Kg 
s.c. for 14 weeks prior to surgery prevented a net loss of lean body mass and muscle 
mass (Weissberger, 2003) At the dose used however growth hormone did not prevent 
the catabolic response to surgery. In addition at 4 weeks post-operatively, muscle
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mass and walking ability were well maintained in patients who received growth 
hormone compared to the placebo group. The conclusion from the study was that 
growth hormone treatment may favourably influence the outcome of elective surgery 
in the elderly.
Patients exposed to acute illness, trauma and major surgery will experience an 
exaggerated catabolic response resulting in the erosion of lean tissue. In many 
immobile patients, premorbid lean tissue reserve is already perilously close to a 
critical threshold below which major functional deficits are seen. This can lead to 
protracted convalescence following surgery requiring intensive rehabilitation. 
Reversal of the age related decline in muscle mass prior to an anticipated catabolic 
state such as major elective surgery, and the prevention of acute catabolic losses, may 
result in earlier discharge from hospital, a faster return to normal activity as well as 
financial savings. Therefore therapy with growth hormone to stimulate an increase in 
pre-operative muscle mass in particular quadriceps has the potential to reduce or 
avoid post operative catabolic losses improve outcomes and reduce hospital stay.
Aims of this study
To determine the feasibility of giving subjects awaiting knee replacement treatment 
with growth hormone, and to see whether growth hormone treatment alters knee 
surgery outcome. Our objectives were as listed below:
Primary objective
• To evaluate the effects of recombinant human growth hormone treatment prior to 
knee replacement surgery on pre-operative lean body mass and quadriceps muscle 
mass as assessed by body composition changes.
Primary endpoints
• change in total pre-operative lean body mass and
• change in pre-operative quadriceps muscle mass.
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Secondary objectives
• To evaluate the effects of GH (Genotropin) treatment prior to knee replacement 
surgery on muscle strength and function and functional ability.
• To assess the effects of Genotropin treatment on outcome of surgery and length of 
post-operative in-patient time.
• To evaluate the safety of Genotropin treatment prior to surgery in subjects 
undergoing total knee replacement for osteoarthritis.
Secondary endpoints
Change in post-operative catabolism
Change in pre- and post-operative muscle strength and function 
Functional ability (4-minute walking distance, WOMAC, AKS scores),
Quality of Life (AIMS, NHP),
Outcome of surgery and number of post-operative in-patient days
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Chapter 2
Clinical Protocol
Study Design
This was a double blind, placebo-controlled, randomised, study. Each growth 
hormone recipient was to be paired with a placebo recipient and the groups were 
stratified according to gender, with equal numbers of male and female subjects to be 
recruited into the study and into each arm of the study.
The dosage regime was to include multiple doses of study medication, with dose 
titration to achieve optimum dose for an individual subject. The target dose was to be 
achieved over six weeks.
40 subjects were to receive either 0.1 lU/kg/day recombinant human growth hormone 
(maximum of 7.5 lU/day) or a matching volume of placebo by a daily injection for 14 
weeks prior to surgery and for 4 weeks after surgery.
Subjects
A total of 32 patients awaiting elective knee replacement surgery for osteoarthriris 
were recruited from the waiting list at the Royal Surrey County Hospital in Guildford.
Inclusion criteria
Age 18 to 85 years.
Haemoglobin > 8.0g/dl.
Aspartate transaminase. Alkaline phosphatase. Bilirubin more than twice the upper 
limit of normal.
Gamma-glutamyl transpeptidase more than three times the upper limit of normal.
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Serum creatinine less than 200umol/l.
Female patients were either post-menopausal or surgically incapable of childbearing 
or practising an acceptable method of birth control.
Fit for surgery.
Able and willing to give fiill informed consent after the nature of the study had been 
fully explained to the patient.
Able to comply with the study medication regime of self administered daily injections 
during the treatment period.
Exclusion criteria
Previous surgery for pituitary adenoma.
Growth hormone deficiency as defined by a history of pituitary disease.
Previously received growth hormone treatment.
Presence of clinically significant disease or dysfunction which is likely to confound 
the defined efficacy endpoints of the study. In particular any disease that would 
impair the anabolic response to growth hormone or may be exacerbated by growth 
hormone treatment.
Diabetes mellitus type 1 and 2: patients who were insulin dependent were excluded, 
patients who were diet controlled only were not excluded.
Liver disease.
Significant renal impairment (serum creatinine greater than 200pmol/l), previous or 
current renal replacement therapy.
Uncontrolled hypothyroidism.
Uncontrolled hypertension (BP consistently more than 170/100 mmHg).
Existing or history of malignancy (with the exception of basal cell carcinoma). 
Administration of medication known to suppress the anabolic effects of growth 
hormone e.g. glucocorticoids.
Revision of previous total knee replacement.
Known or suspected allergy to growth hormone or any of its constituents.
History of drug or alcohol abuse within two years prior to enrolment.
Exposure to another investigational medication or device currently, or within three 
months prior to enrolment.
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Pregnancy or lactation.
Severe congestive heart failure (NYHA class III-IV)
Ethical Consent
The study was approved by the South West Surrey Local Research Ethics Committee. 
All patients provided informed written consent at screening and again at 
randomisation.
Study Protocol
Randomisation
Patients were stratified into two cohorts according to gender. Two separate 
randomisation lists were used, one for each gender. Within each stratum, patients 
were randomised to treatment groups using the method of random permuted blocks 
generated by a pseudo-random code. On successfully completing screening, patients 
were assigned the next available subject number and dispensed the corresponding 
study medication.
Blinding
The study was double blind with respect to the allocation of subjects to treatment or 
placebo. This was achieved by the identical appearance of study medication and 
packaging for each treatment group in each stratum.
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Treatment schedule
In both groups the patients were given study medication by daily self-administered 
subcutaneous injection, (thigh or abdomen) at approximately 10 p.m. Growth 
hormone was administered as Genotropin kindly supplied by Pharmacia and Upjohn. 
The pen devices used for subcutaneous injection are already widely used by growth 
hormone deficient patients receiving therapeutic growth hormone replacement. The 
medication cartridge is placed in the pen and the dose required is selected in much the 
same way as insulin units are selected in diabetic pens. The delivery system and 
medication cartridges were identical for the two treatment groups. The initial 
treatment plan was O.lU/Kg/day s.c. for a total of 18 weeks commencing 14 weeks 
prior to surgery and to continue for 4 weeks postoperatively. The target dose was to 
be achieved over 6 weeks. Patients were given 25 % of the target dose in the first 2 
weeks, 50% of the target dose for the following 2 weeks and then 100% target dose 
for the remainder of the treatment period.
If adverse event occurred the dose was to be reduced by 25% initially.
On some occasions this was not sufficient and so further dose adjustment had to be 
made to allow resolution of the symptoms.
It was quickly noted that the first few patients that received 100% target dose were 
experiencing marked side effects, eg swelling of feet, ankles, hands and face with 
associated parasthesia and also increased arthralgia of many joints not just the 
affected knee. This was obviously undesirable for the study population and also 
threatened to remove blinding throughout the study. We obtained ethical approval for 
a protocol amendment to reduce the target dose to 0.05U/Kg/day, this reduced the 
incidence of possible adverse events to much milder non-specific symptoms. The 
specific details regarding patient adverse events is recorded in the results chapter. If 
surgery was postponed patients continued to take study medication to the date of the 
surgery and for 4 weeks after, to a maximum of 22 weeks.
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Figure 4: Diagram showing the schedule of events
Schematic Diagram of Schedule o f Visits
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Table I: Showing the Events at each Visit
OperationVisit Number
Weeks
Medical History
Examination
Bloods (FBC, 
U&E, LET)
CXR
ECG
Height
Weight
Pulse,BP, 
Temperature
CT
DEXA
Skinfold
thickness
Muscle Strength
Exercise test
Physiotherapy
assessments
(Milestone
prediction
AKS)
Quality o f Life 
Questionnaires 
(NPH, AIMS)
IGF-1
IGFBP-2,
IGFBP-3,
Osteocalcin
DPD & PYD
Adverse Events
Dose Titration
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Patients that had been identified as suitable from the waiting list and also from note 
assessment were initially invited to the hospital for an informal discussion. At this 
point they were given an information sheet to consider at home; all patients were 
advised to discuss taking part with other members of their family and their general 
practitioner. Once a patient confirmed that they would like to take part in the study a 
screening visit was arranged.
Visits
Visit 1 (Week 1)
To establish that all the exclusion and inclusion criteria were met, a full medical 
history was taken and full medical examination was performed. Assessment also 
included the relevant blood tests as stated previously in this chapter, a chest x-ray, 
electrocardiogram (ECG), weight, height, blood pressure, pulse and temperature 
recordings.
Visit 2 (Week 2)
This visit provided the baseline assessments for the study. Patients underwent a 
computerized tomography scan (CT scan) of both thighs to establish the areas of 
muscle and fat. A dual energy x-ray absorptiometry scan (DEXA), provided baseline 
values for fat mass, lean body mass and percentage fat. Body compostion assessments 
recorded were: weight, height, fat mass, skinfold thickness at bicep, tricep, 
subscapular, suprailiac sites, circumference of both thighs, waist and hip 
measurements. Muscle strength was assessed in several groups, biceps, triceps, 
quadriceps, hamstrings and handgrip bilaterally. An exercise test was performed and 
patients were asked to complete a functional assessment questionnaire. The patients 
we assessed by physiotherapists who recorded their current ability. Predictions were 
made as to the expected day post operatively that each individual patient could be 
expected to complete stepwise goals. The physiotherapists also scored the patients 
with the American Knee Score, which is discussed in the next chapter. Quality of life
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was assessed using two questionnaires, The Nottingham Health Profile (Hunt, 1980), 
and the Arthritis Impact Measurement Scale (Meenan, 1980). The patients were 
taught the technique of subcutaneous injection of treatment medication, use of the 
treatment pen, and to record their dosing in their diaries. A blood sample was taken 
for measurement of serum IGF-1, IGFBP2, IGFBP3 at baseline.
Visit 3 (Week 5)
The patients attended the hospital within three weeks to be reassessed. The main goal 
of the visit was to establish that there had not been any adverse events, that the patient 
was confident with their injections and that their dose could be titrated up. Blood was 
taken for serum IGF-1, IGFBP2, IGFBPS.The samples were stored frozen in the 
hospital laboratory freezer, to ensure that regular temperature and maintenance checks 
according to hospital protocol was kept. All samples were analysed blind after the 
study was completed.
Visit 4 and 5
These two “visits” were largely telephone visits to check that all was well with the 
patients. If they were experiencing any adverse advents, they were asked to attend the 
hospital for examination and appropriate baseline blood tests, and the appropriate 
change in their treatment was prescribed.
Visit 6 (Week 16)
This assessment was performed after 14 weeks of treatment in the week before the 
operation. Patients underwent a computerized tomography scan (CT scan) of both 
thighs to establish the areas of muscle and fat. A dual energy x-ray absorptiometry 
scan (DEXA), provided baseline values for fat mass, lean body mass and percentage 
fat. Body compostion assessments recorded were: weight, height, fat mass, skinfold 
thickness at bicep, tricep, subscapular, suprailiac sites, circumference of both thighs.
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waist and hip measurements. Muscle strength was assessed in several groups, biceps, 
triceps, quadriceps, hamstrings and handgrip bilaterally. An exercise test was 
performed and patients were asked to complete a functional assessment questionnaire. 
The patients we assessed by physiotherapists who recorded their current ability. 
Predictions were made as to the expected day post operatively that each individual 
patient could be expected to complete stepwise goals. The physiotherapists also 
scored the patients with the American Knee Score, which is discussed in the next 
chapter. Quality of life was assessed using two questionnaires. The Nottingham 
Health Profile (Hunt, 1980), and the Arthritis Impact Measurement Scale (Meenan, 
1980). A blood sample was also taken for measurement of serum IGF-1, IGFBP2, 
IGFBP3.
The patients were admitted for knee replacement. Where possible the patients had an 
epidural to provide uniform post operative pain management. In some cases however, 
other medical conditions meant that this was not the most appropriate form of 
analgesia, and so other types of analgesia were used. All patients received the same 
type of knee replacement, Johnson and Johnson non porous cruciate retaining femoral 
component, non porous modular tibial tray and posterior lipped tibial insert; some 
patients also required a patella insert. Each patient received the same post operative 
physiotherapy regimes; and this was maintained even if the patient was operated on a 
Friday when physiotherapy would normally not be initiated until the following 
Monday. Treatment with growth hormone/placebo continued for 4 weeks 
postoperatively.
Visit 7 (Week 20)
This visit marked the end of treatment. Patients underwent a computerized 
tomography scan (CT scan) of both thighs to establish the areas of muscle and fat. A 
dual energy x-ray absorptiometry scan (DEXA), provided baseline values for fat 
mass, lean body mass and percentage fat. Body compostion assessments recorded 
were: weight, height, fat mass, skinfold thickness at bicep, tricep, subscapular, 
suprailiac sites, circumference of both thighs, waist and hip measurements. Muscle 
strength was assessed in several groups, biceps, triceps, quadriceps, hamstrings and 
handgrip bilaterally. An exercise test was performed and patients were asked to 
complete a functional assessment questionnaire. The patients we assessed by
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physiotherapists who recorded their current ability. Predictions were made as to the 
expected day post operatively that each individual patient could be expected to 
complete stepwise goals. The physiotherapists also scored the patients with the 
American Knee Score, which is discussed in the next chapter. Quality of life was 
assessed using two questionnaires. The Nottingham Health Profile (Hunt, 1980), and 
the Arthritis Impact Measurement Scale (Meenan, 1980). A blood sample was also 
taken for measurement of serum IGF-1, IGFBP2, IGFBP3. The physiotherapists 
performed the American Knee Scores and also followed up any milestones not 
achieved at discharge.
Visit 8 (Week 24)
This was the last study visit, patients were 3 months post operation and 2 months 
treatment free. Patients underwent a computerized tomography scan (CT scan) of both 
thighs to establish the areas of muscle and fat. A dual energy x-ray absorptiometry 
scan (DEXA), provided baseline values for fat mass, lean body mass and percentage 
fat. Body compostion assessments recorded were: weight, height, fat mass, skinfold 
thickness at bicep, tricep, subscapular, suprailiac sites, circumference of both thighs, 
waist and hip measurements. Muscle strength was assessed in several groups, biceps, 
triceps, quadriceps, hamstrings and handgrip bilaterally. An exercise test was 
performed and patients were asked to complete a functional assessment questionnaire. 
The patients we assessed by physiotherapists who recorded their current ability. 
Predictions were made as to the expected day post operatively that each individual 
patient could be expected to complete stepwise goals. The physiotherapists also 
scored the patients with the American Knee Score, which is discussed in the next 
chapter. Quality of life was assessed using two questionnaires. The Nottingham 
Health Profile (Hunt, 1980), and the Arthritis Impact Measurement Scale (Meenan, 
1980). A blood sample was also taken for measurement of serum IGF-1, IGFBP2, 
IGFBP3.
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Treatment Compliance
Patient’s compliance was checked firstly by providing the patients with diaries to 
record the dose and time of their injection. Patients brought back all their used 
cartridges at each visit and these were accounted for in pharmacy. At all hospital 
visits, serum for IGF-1 was taken and stored, so that once the study was completed 
compliance could be verified.
Adverse Events
Adverse events were to be coded using the medDRA dictionary and assigned a body 
system and preferred term. The number and percentage of subjects with at least one 
adverse event starting whilst on treatment (treatment-emergent) was to be summarised 
by treatment group, as was the number and percentage of subjects with at least one 
serious adverse event. The number and percentage of subjects with an adverse event 
starting whilst on-treatment was to be summarised by body system, preferred term 
and treatment group. Adverse events were also to be summarised by severity and 
relationship to study medication.
Safety Evaluation
All patients were to be presented for the safety population.
56
Chapter 3 
Methods
Laboratory Assays 
IGF-1
IGF-1 was measured using Nichols institute Diagnostics chemiluminescence 
immunoassay. This assay is a two site chemiluminescence assay for the measurement 
of IGF-1 in human serum. Acridium esters emit light upon treatment with hydrogen 
peroxide and an alkaline solution. The Trigger 1 solution contains hydrogen peroxide 
in dilute acid and Trigger 2 solution contains dilute sodium hydroxide. The system 
automatically injects Trigger solutions 1 and 2 into the wells which oxidise the 
acridium ester. The oxidised product is in an excited state. The subsequent return to 
the ground state results in emission of light which is quantified in 2 seconds and is 
expressed in relative light units (RLU) by the integrated system luminometer. The 
antibody to the C-terminal with the amino acid sequences of 62-70 is biotinylated for 
capture and the antibody to the amino acid sequences of 1-23 and 42-61 is labelled 
with acridium ester for detection.
The patient sample is acidified to separate IGF-1 fi*om IGFBPs, then excess IGF-II is 
added in the assay to block IGFBP binding sites firom recombining with the released 
IGF-1. The acidified patient sample is incubated simultaneously with the biotinylated 
capture antibody, excess IGF-II, and the acridium ester labelled tag antibody. During 
the first incubation, IGF-1 in the sample forms a sandwich complex with the capture 
antibody and the acridium labelled antibody. After the initial incubation period 
streptavidin coated magnetic particles are added to the reaction mixture and a second 
incubation follows. The streptavidin coated magnetic particles allow for a highly 
specific and efficient means of binding the sandwich complex to the solid phase via 
the high affinity interaction between biotin and streptavidin. Free labelled antibody is 
separated from the labelled antibody bound to the magnetic particles by aspiration of 
the reaction mixture and subsequent washing. The wells containing the washed
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magnetic particles are transported to the system luminometer, which automatically 
injects Trigger 1 and Trigger 2, initiating the chemiluminescence reaction. The light 
is quantitated by the luminometer and expressed as RLU. The amount of bound 
labelled antibody is directly proportional to the concentration of IGF-1 in the sample.
The assay runs on the Nichols Advantage speciality system. The sample is placed in 
the designated sample racks and these racks placed in the sample loading area. The 
system performs an assay specific on board dilution by first pipetting 13 pi of the 
sample and 400 pi of the acidification buffer into one well of the cuvette. 50 pi of the 
acidified sample mixture is then pipetted and added to a mixture of 100 pi of of 
biotinylated goat polyclonal antibody, 50 pi of the IGF-II solution and 50 pi of the 
acridium labelled goat polyclonal antibody in the next well of the cuvette. The 
cuvette strip is transported to the incubation chamber and incubated for 20 minutes at 
37®C. After this initial incubation, 25 pi of streptavidin coated magnetic particles are 
added to each well. The incubation is prolonged for a further 10 minutes at 37®C. 
After the entire incubation the wells are washed and measured in the measuring 
chamber. The coefficient of variation for this assay was 4.8%.
IGFBP-2
IGFBP-2 levels are determined by an in-house RIA technique, in which standards 
(containing recombinant IGFBP-2), samples and controls are incubated at 4°C 
overnight with a rabbit polyclonal IGFBP-2 antiserum and iodinated IGFBP-2.
The free and antibody-bound tracer fractions are separated by the addition of a solid 
phase anti-rabbit globulin. Following sedimentation by centrifugation and aspiration 
of the supernatants, the pellets are counted for 60 seconds in a gamma counter and the 
IGFBP-2 concentrations are read against the standard curve. Control and test sera are 
diluted 1:50 in assay diluent prior to assaying.
The assay has a limit of detection of 0.03mg/L and has inter and intra-assay CVs of 
between 7% and 18%. No cross-reactivity with other IGFBPs occurs in this assay.
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IGFBP-3
The IGFBP-3 assay is a two site immunochemiluminometric assay. Two specific 
monoclonal antibodies to IGFBP-3 are used. One monoclonal antibody is biotin 
labelled and used as capture, and the second monoclonal antibody is labelled with 
acridinium-ester and used for detection. First sample is pre-diluted 1:50 by the 
instrument into a separate cuvette well. Then the 1:50 diluted sample, the two anti- 
IGFBP-3 antibodies, streptavidin-coated magnetic particles, and assay buffer are 
pipetted into another well and allowed to incubate for 32 minutes at 37°C. The 
formation of a soluble sandwich complex occurs only in the presence of IGFBP-3 
molecules that bridge the two antibodies. Because of the high affinity between biotin 
labelled antibody to streptavidin, the sandwich complex is captured onto the 
streptavidin magnetic particles. The captured complex bound to the magnetic particles 
is then washed by the system to remove unbound components. The cuvette wells 
containing the washed magnetic particles are transported into the system 
luminometer, which automatically injects Trigger 1 and Trigger 2, initiating the 
chemiluminescence reaction. The light quantitated by the luminometer is expressed as 
relative light units (RLU). The amount of RLU is directly proportional to the amount 
of acridinium-ester labeled antibody bound to IGFBP-3. The instrument specific 
software then compares the RLU signal from the assay output to a stored calibration 
curve in which known concentrations of IGFBP-3 have been assayed using the same 
method. The RLU signal when read-off the stored calibration curve is directly 
proportional to the IGFBP-3 concentration in the sample.
The sample is placed in the designated sample racks and these racks placed in the 
sample loading area The system first performs a 1:50 dilution of specimen by 
pipetting 5 pL of sample and 245 pL of sample diluent into a cuvette well. From this 
well, 75 pL of diluted sample is pipetted to second well with 225 pL of assay buffer. 
To this same well, 23 pL of biotinylated antibody, 45 pL of acridinium ester labeled 
antibody, and 25 pL of streptavidin-coated magnetic particles are added. The cuvette 
is then transported to the 37°C incubator and incubates for approximately 32 minutes. 
When incubation is complete, the cuvette is transported to the wash chamber and the 
streptavidin-coated magnetic particles are captured and washed. The well is then
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measured in the measuring chamber. The amount of RLUs is directly proportional to 
the amount of labeled acridinium ester anti-IGFBP-3 bound to the particle. Results are 
interpolated via a manufacturer generated 10 point Master Curve, which is system- 
specifically adjusted by running 2-point Calibrators A and B. The RLU signal when 
read-off the stored calibration curve is directly proportional to the IGFBP-3 
concentration in the sample. The coefficient of variation for this assay was between 
6.0-16.7%.
Clinical Efficacy Assessments
The primary efficacy assessment in the study is an assessment of the effects of GH on 
the total pre-operative lean body mass, and pre-operative quadriceps mass. Lean body 
mass and fat mass were measured by DEXA scan prior to treatment with GH or 
placebo and repeated at visits during the study as described above. Quadriceps mass 
and thigh fat content were measured by CT scan using cross sectional cuts to 
determine the areas of muscle and fat at a point mid thigh, at the same time points.
Body composition
An Hologic QDR500 X-Ray Bone Densitometer was used to measure the fat mass 
and lean mass of the whole body, trunk and limbs of our patient group (Prior 
BM,1997; Kohrt WM, 1998)
The software of this machine ensures that the same areas are measured on each scan 
of the patient, and calculates values without using height and weight data and so 
ensures a high level of accuracy. The knee prosthesis does not interfere with the 
assessment of fat or lean mass in any of the body regions analysed.
A Siemans Spiral CT scanner, provided the muscle and fat area of the mid thigh for 
both legs. (Bulcke et al, 1979). Patients were placed on the table with feet tied 
together for each scan. In order to ensure that the same slice was measured on each 
occasion the femoral head was used as a reference point, and slices were measured at
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10 cm intervals until 30 cm below the femoral head. Muscle and fat were identified 
using the Hounsfield numbers 20-100 and then expressed in units of cm2. (Cuneo et 
al, 1991).
Bioelectrical impedance was measured using the same Tanita (TBF 105)(Tanita Corp. 
Illinois USA). This method depends on the principal that lean body mass contains 
virtually all the water and conducting electrolytes and is therefore, a good conductor. 
In contrast, fat tissue contains little water and is therefore, a very poor conductor of 
electricity. The bioimpedance analyser applies a low frequency alternate current to a 
subject and measures body impedance. Based on equations, which take into account 
body weight, height and gender, the measured impedance can be converted into an 
estimate of total body water. As the hydration of lean tissue is assumed to be constant 
lean body mass can be calculated. Fat mass is then obtained as the difference between 
total body weight and lean body mass.
The same investigator assessed height (m) using a fixed wall measure, skinfold 
thickness using Holtain skinfold callipers (mm), and waist/hip circumference ratio 
and circumference of both legs(cm).
Muscle Strength and Function
Muscle strength -  peak voluntary isometric force, recorded in Newtons was assessed 
by the same investigator using a Microfet 2 hand held electrodynamometer. Strength 
was recorded in biceps, triceps, quadriceps and hamstrings muscle groups bilaterally. 
Patients were assessed in the same straight back chair. The force achieved from three 
efforts was recorded (Cuneo RC, 1991).
Handgrip strength was assessed bilaterally using the Jamar hand dynamometer and 
was recorded in Kg/force. Patients were assessed in the same straight back chair and 
the force achieved from three efforts was recorded.
Functional ability was assessed using a 4 minute exercise test. Patients were asked to 
walk at their fastest comfortable pace for 4 minutes on a prepared walking circuit - a
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flat surface between two points 33m apart, total distance completed in the time was 
recorded in metres.
Functional ability was also assessed using. The Western Ontario and McMaster 
Osteoarthritis Index (WOMAC), (Bellamy, 1998).
Knee function with respect to stability and pain was scored by the physiotherapists for 
each patient at each visit described in the method. The score was derived from the 
system devised by the American Knee Society for the evaluation of replacement 
surgery. Using this same system a score was obtained for knee function. The 
physiotherapists recorded the current ability of the patient by reference to, gait 
pattern, stairs pattern and for the affected leg the active range of knee flexion, straight 
leg raise ability and standing from sitting ability. The key physiotherapy milestones 
are; day achieved 90 active range of knee flexion, day achieved straight leg raise 
without lag (second of two consecutive days) and day achieved sit to stand with 
operated leg out in front. The day these milestones were expected to be achieved was 
recorded at each physiotherapy assessment pre-operatively; in addition to this, 
predictions were made as to the day various gait and stairs pattern milestones would 
be achieved. A gait pattern of step to or step through was used with walking aid; 
frame, elbow crutches, 2 sticks, 1 stick or no walking aid recorded in addition. Stairs 
pattern was recorded as not able, hands/knees, alternate steps, 1 step at a time and the 
use of banister or aid was recorded in addition.
Quality of Life
The Nottingham Health Profile (Hunt, 1980), was derived from the scores for the 
following sections: physical activities, pain, sleep, social isolation, emotional 
reactions and energy levels. The Arthritis Impact Measurement Scale (Meenan, 1980), 
was derived the scores for mobility, physical activity, dexterity, household activity, 
social activity, activities of daily living, pain, depression and anxiety. A measure of 
total health was obtained by adding the values for the six scales mobility, physical 
activity, household activity, dexterity, pain and depression. The change in the measure 
of total health was to be derived as the measure of total health at each visit minus the 
value at randomisation.
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Primary objective
• To evaluate the effects of recombinant human growth hormone treatment prior to 
knee replacement surgery on pre-operative lean body mass and quadriceps muscle 
mass as assessed by body composition changes.
Primary endpoints
• change in total pre-operative lean body mass and
• change in pre-operative quadriceps muscle mass.
Secondary objectives
• To evaluate the effects of Genotropin treatment prior to knee replacement surgery 
on muscle strength and function and functional ability.
• To assess the effects of Genotropin treatment on outcome of surgery and length of 
post-operative in-patient time.
• To evaluate the safety of Genotropin treatment prior to surgery in subjects 
undergoing total knee replacement for osteoarthritis.
Secondary endpoints
• Change in post-operative catabolism
• Change in pre- and post-operative muscle strength and function
• Functional ability (4-minute walking distance, WOMAC, AKS scores) ,
• Quality of Life (AIMS, NHP),
• Outcome of surgery and number of post-operative in-patient days 
Statistical analysis
Three analysis populations were defined:
Safety Population
The safety population consisted of all subjects who received at least one dose of study 
medication.
Intention-to-Treat Population
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The Intention-to-Treat Population consisted of all subjects in the safety population. 
This data set was to be the primary population for the efficacy analyses.
Per Protocol Population
The Per Protocol Population consisted of all subjects in the Intention-to-Treat 
Population who had not violated any major entry criteria, who had satisfied critical 
protocol adherence criteria affecting the assessment of efficacy, and who had not 
withdrawn fi-om the study for any reason. This data set was to be the secondary 
population for the efficacy analysis.
All data for subjects who met the following criteria were to be excluded from the Per 
Protocol Population:
• No informed consent,
• Not awaiting elective total knee replacement for osteoarthritis,
• Not between 18 and 85 years at screening,
• Any concomitant disease at screening which would affect the anabolic action of 
growth hormone,
• Any concomitant medication, at any time during the study, which is known to 
suppress the anabolic effects of growth hormone,
• Withdraw prematurely for any reason,
• Were administered with the wrong study medication,
• Elective total knee replacement either was not performed, or had complications 
which affect the post-surgery measurements of primary efficacy.
Continuous variables were summarised for each treatment group using the following 
descriptive statistics: number of observations (N), mean, standard deviation (SD), 
median, minimum and maximum.
Categorical variables were summarised for each treatment group using frequencies 
and percentages. Percentages were to be calculated based on the number of subjects 
in the safety population, the Intention-to-Treat Population or the Per Protocol 
Population, as appropriate.
For the primary efficacy variables, an estimate of the treatment effect and the 
accompanying 95% confidence interval were to be provided. These estimates were to
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be calculated from a parametric or non-parametric analysis. Statistical significance 
was to be based on a two-sided p-value at 0.05 significance level.
Subject disposition tables and demography tables were to be based on all subjects 
randomised. Safety tables were to be based on the safety population. Efficacy tables 
were to be based on the Intention-to-Treat Population or the Per Protocol Population. 
All listings were to be based on all subjects randomised.
Subject Disposition
The number of subjects randomised, receiving treatment, and discontinuing from the 
study (with reason for discontinuation), were to be presented by treatment group and 
overall.
Demographic, Baseline and Background Characteristics
Age at randomisation, gender, and ethnic origin were summarised by treatment group 
for the safety population. The number and percentage of males/females and for each 
ethnic origin category were to be presented. Medical history was to be listed and 
summarised by presenting the number and percentage of abnormalities in each body 
system and preferred term for each treatment group.
Efficacy Evaluation
All summaries and statistical analyses were to be presented for the Intention-to-Treat 
Population. Confirmatory analyses were to be presented for the Per Protocol 
Population.
Primary Efficacy Analysis
The change in lean tissue and quadriceps muscle mass were summarised for each 
treatment group. The lean tissue mass and the quadriceps muscle mass were also
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analysed for the leg that had been operated on and for the leg that had not been 
operated on.
The changes in the lean tissue and muscle mass were compared between the treatment 
groups using an analysis of covariance allowing for age and gender. The adjusted 
mean difference between treatment groups in the change from baseline was presented 
along with the associated 95% confidence intervals and the p-value. Where the 
assumptions of normality and homogeneity of variances underlying this analysis were 
not met, a non-parametric analysis. Van Elteren’s test, was performed comparing the 
treatment groups while stratifying for age and gender.
Secondary Efficacy Analysis
The secondary analyses were considered exploratory in nature and as such, no 
significance tests were performed.
Body composition
The change in post-operative catabolism was to be assessed by the change in lean 
tissue mass as measured by the DEXA. The change in post-operative catabolism was 
to be derived for the post-operative assessment (at study termination -  Visit 8) as the 
post-operative measurement minus the pre-operative measurement (Visit 6). The 
change was summarised for each treatment group. The lean tissue mass was also to be 
summarised pre and post-operatively for each treatment group.
Height; weight; percentage fat, waist/hip circumference ratio and the circumference of 
the leg were recorded at each visit for each treatment group. The average skin fold 
thickness was to be calculated across the four sites (bicep, tricep, subscapular and 
supra-iliac) for each patient visit and summarised for each treatment group and visit.
Muscle Strength and Function
The change in handgrip strength, electrodynamometer readings and strength of 
quadriceps and biceps were to be calculated as the post randomisation values minus 
the randomisation value. The randomisation value and the changes post randomisation 
were summarised by treatment group.
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The 4-minute walking distance was summarised at randomisation (Visit 2), pre­
surgery (Visit 6), post surgery (Visit 7) and at study termination (Visit 8) for each 
treatment group.
The WOMAC index score for each dimension: pain, stiffness and physical function 
was summarised by presenting the N, median, minimum and maximum by treatment 
group for each visit.
The knee and function score (low score indicates severe problems, high score 
indicates no problems) were to be derived from the system devised by the American 
Knee Society (AKS) for the evaluation of replacement surgery for each patient visit. 
The total knee score was summarised by treatment group.
Outcome of Surgery
The key physiotherapy milestones were; day achieved 90% active range of knee 
flexion; day achieved straight leg raise without lag (second of two consecutive days) 
and day achieved sit to stand with operated leg in front. These milestones were 
summarised by calculating the Kaplan-Meier estimate of the median time (in days) to 
achieve each milestone by treatment. The time to achieve each milestone was to be 
calculated as the date of achieving the milestone minus date of surgery + 1. Where a 
subject did not achieve a key milestone within the 7 days of physiotherapy, the value 
was to be censored at 7 days.
The number of in-patient days was to be calculated as the date the patient was 
medically ready for discharge from hospital minus the date of surgery + 1. The 
number of post-operative in-patient days was to be summarised by treatment group.
Quality of Life
The NHP questionnaire was to be summarised by deriving the score for the following 
sections: physical activities; pain; sleep; social isolation; emotional reactions and 
energy levels for each patient at each visit (randomisation, pre-operative, post­
operative and termination visits). The sections were to be summarised by calculating 
the N, median, minimum and maximum by treatment group for each visit.
The AIMS questionnaire was to be summarised by deriving the scales for mobility, 
physical activity, dexterity, household activity, social activity, activities of daily 
living, pain, depression and anxiety for each patient at each visit (randomisation, pre­
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operative, post-operative and termination visits). A measure of total health was to be 
derived by adding the values for the six scales: mobility; physical activity; household 
activity; dexterity; pain and depression. The change in the measure of total health was 
to be derived as the measure of total health at each visit minus the value at 
randomisation. The scales were to be summarised by presenting the N, median, 
minimum and maximum by treatment group for each visit. The change in the measure 
of total health was to be summarised by presenting the N, median, minimum and 
maximum by treatment group for each visit.
Laboratory data
The change from randomisation value for each post randomisation visit was to be 
derived for each patient for the following serum chemistry parameters: IGF-I, 
IGFBP2 and IGFBPS. The value at randomisation and the changes from 
randomisation were to be summarised by treatment group and visit. The number and 
percentage of subjects with markedly abnormal laboratory (clinically significant) 
values were to be summarised for the haematology parameters and the serum 
chemistry parameters by treatment group. The mean changes were to be plotted by 
treatment group and visit.
Vital signs
Systolic blood pressure, diastolic blood pressure, pulse rate, temperature and weight 
were to be summarised at each visit by treatment group. The changes from the 
randomisation visit were to be summarised similarly for all post randomisation visits 
by treatment group.
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Chapter Four
Results
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Subject Disposition
In total, 32 subjects were sereened. Subjects were randomised into treatment or 
plaeebo group. Figure 5 shows the number of subjects screened, randomised, 
withdrawn and completed in both study populations.
Figure 5: Showing the numbers of patients involved at each stage of the study
Genotropin
N=14
Completers
N=27
Subjeets Screened 
N=32
Plaeebo
N=13
Subjects
Randomised
N=32
Intention-to-Treat
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N=32
Genotropin
N=16
Per Protoeol 
Population 
N=26
Genotropin
N=14
Genotropin
N=16
Plaeebo
N=16
Plaeebo
N=16
Placebo
N=12
(N=l) 
Consent Withdrawn 
(N=2)
Other (N=2)
Withdrawals (N=5) 
Adverse Event
Consent Withdrawn 
(N=l)
Other (N=l)
Genotropin (N=16)
(N=l) 
Consent Withdrawn
Plaeebo (N=3) 
Adverse Event
(N=l) 
Other (N=l)
In total, 27 subjects completed the trial after 26 weeks of treatment, and 5 subjects 
were withdrawn after randomisation for the reasons shown in Table I.
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Table II: Reasons for Withdrawal by Treatment Group
Reason for 
Withdrawal
Genotropin
(N=16)
Placebo
(N=16)
Total
(N=32)
Adverse Event 0 1 1
Consent Withdrawn 1 1 2
Other reason 1 1 2
Total 2 3 5
The most eommonly reported reason for withdrawal in both treatment groups was 
withdrawal of consent. One subject withdrew due to a serious adverse event. Adverse 
Events leading to withdrawal are described below. Other reasons for withdrawal were
1) subject 9 in the Genotropin group had coronary artery disease, whieh was 
eonsidered too severe for the operation to go ahead,
2) subjeet 29 in the Placebo group had the operation changed from knee replaeement 
to hip replaeement.
Withdrawal occurred between 76 and 123 days after study treatment began .
Protocol Deviations
Six subjeets were exeluded from the Per Protocol Population, two in the Genotropin 
group and four in the Placebo group. Five subjeets were withdrawn prematurely 
(subjects 9 and 24 in the Genotropin group and subjeets 11, 16 and 29 in the Placebo 
group). Subjeet 36 in the Placebo group had complications with their elective knee 
replacement surgery. Three of the withdrawn subjeets (subject 9 in the Genotropin 
group and subjects 16 and 29 in the Placebo group) did not have their elective knee 
replaeement surgery performed.
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Demographic, Baseline and Background Characteristics
The following Table III gives an overview of the demographic data for the subjeets 
randomised.
Table III; Demographic Data
Genotropin
(N=16)
Placebo
(N=16)
Total
(N=32)
Sex (male/female) 8/8 8/8 16/16
Age (years)* 70.7+7.13 66.8±8.05 68.8+7.74
Age (<=70/>70) 7/9 10/6 17/15
Height (cm)* 166.25+10.063 165.31±10.203 165.78+9.980
Weight (kg)* 80.45+13.726 82.88114.560 81.66+13.974
* For age, height and weight, mean values ± standard deviation is given.
The treatment groups were comparable. All subjects were white. A total of 15 
subjects were aged over 70 years, nine subjects in the Genotropin group and six 
subjeets in the Placebo group.
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Table IV: Medical History and Physical Findings Active at Screening
Therapeutic Class Genotropin
(N=16)
Plaeebo
(N=16)
Total
(N=32)
Musculoskeletal
Disease
16 16 32
Neurology 4 2 6
Cardiology 3 0 3
Renal 2 1 3
Opthalmology 1 1 2
Gastroenterology 1 1 2
Respiratory 1 0 1
medical history and physical findings were musculoskeletal
Study Treatment
32 subjects (16 subjects in each treatment group) received 25% of O.lIU/kg/day 
Genotropin or Placebo by daily injeetion for the first two weeks of the trial. All 
subjects received the correct study medication. Dose titration and reduction was to be 
made in steps of 25%. The dose was increased to 50% of O.lIU/kg/day for all 
subjects, and was increased to 75% or 100% of O.lIU/kg/day for six subjeets (three in 
each treatment group). The dose was reduced by 4% for a subject in the Genotropin 
who was on 25%, after the occurrence of an adverse event. Safety was reviewed 
during the titration period. If adverse events occurred during titration, the dose was to 
be reduced. Ten subjects in the Genotropin group and one subject in the Placebo 
group had their dose reduced due to adverse events. Adverse Events related to study 
medication and adverse events with an action of study medication dose change are 
described below.
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Operative Procedures
After 14 weeks of study treatment, elective knee surgery was performed on 29 
subjects (15 in the Genotropin group and 14 in the Plaeebo group). One subject in the 
Placebo group had eomplications with their elective knee replacement surgery. She 
was found to have a ligament rupture at the operation.
Clinical Efficacy Assessments 
Total lean body mass
The first primary parameter for analysis was the change from randomisation in total 
pre-operative lean body mass after 14 weeks of treatment. Table V, shows the results 
for the Intention-to-Treat population and Table VI, shows the results for the Per 
Protoeol Population.
Table V: Total Lean Mass (g) at Randomisation and Preoperatively in by 
Treatment Group -  Intention-to-Treat Population
Genotropin Placebo P-value# (95% C.I.)*
Randomisation mean 
(visit 2)
49403.3 51284.6
Pre-Operative mean 
(visit 6)
51201.6 51302.6
Change from 
Randomisation (mean ± 
SD)
2221+2415.6 18.0+1098.0 0.0142 (-3948.3- 
575.1)
# P-value from Van Elteren’s Test with age and gender as stratification factors. * 95% 
Confidence Interval based on Wileoxon Rank Sum Test unadjusted for age or gender 
with P-value=0.0161.
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Table VI: Total Lean Tissue Mass (g) at Randomisation and Pre-Operative by 
Treatment Group -  Per Protocol Population
Genotropin Placebo P-value# (95% C.I.)*
Randomisation mean 
(visit 2)
49482.2 51058.8
Pre-Operative mean 
(visité)
51757.3 51192.8
Change from 
Randomisation (mean ± 
SD)
2275.1+2497.
3
134.1±1227.6 0.0436 (-3987.3, - 
121.4)
# P-value from Van Elteren’s Test with age and gender as stratification factors. * 95% 
Confidence Interval based on Wilcoxon Rank Sum Test unadjusted for age or gender 
with P-value=0.0588.
The increase in tissue mass in the Genotropin group was significantly greater than in 
the Placebo group for both the Intention-to-Treat Population (P=0.0142) and the Per 
Protocol Population (P=0.0436) demonstrated using non-parametric analysis -  Van 
Elteren’s test. Statistical significance testing was also performed using the Wilcoxon 
Rank Sum test, unadjusted for age or gender. The results obtained were similar to 
those obtained using the stratified Van Elteren test for both the Intention-to-Treat 
Population (P=0.0161) and the Per Protocol Population (P=0.0588). The confidence 
intervals reported in Tables V and VI are based on the unstratified Wilcoxon Rank 
Sum test.
Similarly, increase in lean tissue mass was significantly higher in the Genotropin 
group than in the Placebo group for the operated leg and for the non-operated leg and 
for both the Intention-to-Treat and the Per Protocol Populations (see tables VII -  X)
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Table VII: Lean Tissue (g) Operated Leg - Placebo Group -  Intention to treat
Population
Visit 2 Visit 6 Visit 8
Number 12 12 12
Mean 7476.5 7556.4 7777.6
Standard deviation 1719.4 19828 1955.4
Median 7306.1 7252.5 7695.9
Range (4771,10262) (4725, 11002) (5210, 11477)
Table VIII: Lean Tissue (g) Operated Leg - Genotropin Group -  Intention to 
treat Population
Visit 2 Visit 6 Visit 8
Number 14 14 14
Mean 7567.6 8014.3 7792.9
Standard deviation 1834.3 1930.0 2197.2
Median 7506.4 7909.2 7611.4
Range (4886,11603) (5325, 11536) (4672, 12378)
Table IX: Lean Tissue (g) Non - Operated Leg - Placebo Group -  Intention to 
treat Population
Visit 2 Visit 6 Visit 8
Number 12 12 12
Mean 7681.4 7579.4 7768.2
Standard deviation 2019.3 2103.5 22259.4
Median 7645.9 7165.3 7418.4
Range (4702,11388) (4673,11308) (4624,11840)
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Table X: Lean Tissue (g) Non - Operated Leg - Genotropin Group -  Intention
to treat Population
Visit 2 Visit 6 Visit 8
Number 14 14 14
Mean 7827.6 8098.2 7716.1
Standard deviation 2050.0 2200.4 2250.6
Median 7951.0 7870.6 7683.1
Range (5329,12958) (5407, 13419) (5245, 12981)
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Change in Post-Operative Catabolism
The first secondary parameter for analysis was the change from Visit 6 in total lean 
body mass after surgery. Table XI, shows the results for the Intention-to-Treat 
Population and Table XII shows the results for the Per Protocol Population.
Table XI: Total Lean Tissue Mass (g) Pre and Post operatively by Treatment 
Group in Intention-to-Treat Population
Genotropin Placebo p value
Pre-Operative mean (Visit 6) 51201.6 51302.6 NS
Post-Operative mean (Visit 8) 49697.3 51271.0 NS
Change from Visit 6 (mean ± 
SD)
-2060.0±2191.4 345.8+1506.2
Table XII: Total Lean Tissue Mass (g) Pre and Post-operatively by Treatment 
Group -  Per Protocol Population
Genotropin Placebo p value
Pre-Operative mean (Visit 6) 51757.3 51192.8 NS
Post-Operative mean (Visit 8) 49697.3 51622.3 NS
Change from Visit 6 (mean + SD)
2060.0+21
91.4
429.5+1616.1 NS
There was a non-significant decrease in total lean tissue mass seen in the Genotropin 
group, while a non-significant increase was seen in the Placebo group. Similar results 
were found in the summaries of change from Visit 6 in total lean tissue mass for the 
operated leg and the non-operated leg, for both the Intention-to-Treat and the Per 
Protocol Populations - see below
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Table XIII: Change From Randomisation in Pre-Operative Lean Tissue Mass (g) 
-  Operated Leg Intention-to-Treat Population
Genotropin Placebo p-value
Number 15 16
Mean 438^ 76.7 0.0157
Standard deviation 517.9 328.8
Median 339J -35.2
Range (-374,1687) (-397,740)
p-value from Van Elteren's test ^vith age and gender as strafication factors.
Table XIV: Change From Randomisation in Pre-Operative Total Tissue Mass 
(g) -  Non Operated Leg Intention-to-Treat Population
Genotropin Placebo p-value
N 15 16
Mean 305.1 -48.3 0.0224
Standard deviation 445.3 375.5
Median 460.1 -54.7
Range (-570,865) (-732,545)
p-value from Van Elteren’s test with age and gender as stratification factors.
Table XV: Change From Randomisation in Pre-Operative Lean Tissue Mass (g)- 
Operated Leg Per Protocol Population
Genotropin Placebo p-value
Number 14 12
Mean 446.7 79.9 0.0276
Standard Deviation 536.4 340.2
Median 389j 34.2
Range (-374,1687) (-397, 740)
p-value from Van E teren’s test with age and gender as stratification factors.
79
Table XVI: Change From Randomisation in Pre-Operative Lean Tissue Mass (g) 
- Non Operated Leg Per Protocol Population
Genotropin Placebo p-value
Number 14 12
Mean 270.6 -101.9 0.0257
Standard deviation 440.9 395^
Median 318.8 -54.7
Range ^^70,865) (-732,545)
p-value from Van Elteren's test with age and gender as stratification factors. 
Quadriceps muscle mass
Changes in preoperative quadriceps muscle mass
The second primary parameter for analysis was the change from randomisation in 
total pre-operative quadriceps muscle mass after 14 weeks of treatment. Table XVII 
shows the results for the Intention-to-Treat Population and Table XVIII shows the 
results for the Per Protocol Population.
Table XVII: Quadriceps Muscle Mass (g) at Randomisation and Pre- 
operatively by Treatment Group -  Intention to Treat Population
Genotropin Placebo 95% Cl
Randomisation mean 137.7 144.5
Pre-Operative mean 140.2 143.4
Change from 
Randomisation (mean ± 
SD)
3.7+9.17 -1.1+10.77 (-2.80, 12.80)
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Table XVIII: Quadriceps Muscle Mass (g) at Randomisation and pre- 
operatively by Treatment Group -  Per Protocol Population
Genotropin Placebo 95% Cl
Randomisation mean 141.6 138.7
Pre-Operative mean 145.6 139.7
Change fi*om 
Randomisation (mean ± 
SD)
3.9+9.47 1.1±11.43 (-5.49,11.98)
On average, an increase in quadriceps muscle mass was seen in both the Genotropin 
and Placebo groups for both the Intention-to-Treat and the Per Protocol Populations.
The assumptions underlying the plaimed analysis of covariance were satisfied. The 
95% confidence intervals for the estimated difference of the adjusted mean change 
for the Genotropin group -  Placebo group at Week 14, as presented in Table XVII and 
Table XVIII, show no evidence to suggest that Genotropin is different from Placebo. 
For both the Intention-to-Treat and the Per Protocol Populations, the 95% confidence 
interval encompasses zero.
Similarly, analyses of change from randomisation in quadriceps muscle mass for the 
operated leg for both the Intention-to-Treat and the Per Protocol Population showed 
no difference in the treatment groups.
A similar finding is seen in both the operated and non operated legs.
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Change in Post-Operative Muscle Strength and Function
Table XIX shows the results for the change from Visit 6 in quadriceps total muscle 
mass after surgery for the Intention-to-Treat Population and Table XX shows the 
results for the Per Protocol Population.
Table XIX: Total Quadriceps Muscle Mass (g) Pre and post operatively by 
Treatment Group -  Intention-to-Treat Population
Genotropin Placebo
Pre-Operative mean (Visit 6) 140.2 143.4
Post-Operative mean (Visit 8) 132.3 129.8
Change from Visit 6 (mean ± SD) -13.3±8.41 -10.2+6.89
Table XX: Total Quadriceps Muscle Mass (g) Pre and post-operatively by 
Treatment Group -  Per-Protocol Population
Genotropin Placebo
Pre-Operative mean (Visit 6) 145.6 139.7
Post-Operative mean (Visit 8) 132.3 130.1
Change from Visit 6 (mean ± SD) -13.3+8.41 -9.6+7.32
On average, a decrease in total lean tissue mass was seen in both the Genotropin and 
Placebo groups.
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Fat Mass
There was a non significant decrease in fat mass in patients treated with growth 
hormone.
Table XXI: Percentage Fat (%) -  Placebo -  Intention to treat Population
Visit 2 Visit 6 Visit 8
Number 12 12 12
Mean 35.75 37.29 3336
Standard deviation 9.044 8376 8.534
Median 34.25 36.00 33.00
Range (22.00, 49.50) (22.50, 50.50) (20.50, 48.00)
Table XXII: Percentage Fat (%) -  Genotropin -  Intention to treat Population
Visit 2 Visit 6 Visit 8
Number 14 14 14
Mean 30.25 29.04 27.43
Standard deviation 8.88 8.023 9.571
Median 26.25 2635 27.25
Range (18.5,44.5) (20.50,41.50) (10.50, 41.00)
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Functional Ability
The summary of change from randomisation in left hand grip strength (kg/force) for 
the Intention-to-Treat Population showed a reduction, on average, in the Genotropin 
group and an increase, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
Table XXIII: Change from Randomisation in Left Hand Grip Strength 
(kg/force) -  Placebo Group -  Intention to treat Population
Visit 2 Visit 6
Number 16 16
Mean 30.140 31.003
Standard deviation 12.7746 13.3952
Median 30.485 30.650
Range (13.30, 56.00) (15.30,58.67)
Table XXIV: Change from Randomisation in Left Hand Grip Strength 
(kg/force) -  Genotropin Group -  Intention to Treat Population
Visit 2 Visit 6
Number 16 15
Mean 25.930 23381
Standard deviation 8.9166 8.7463
Median 27.170 26.00
Range (13.00, 40.30) (8.67, 34.67)
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The summary of change from randomisation in right hand grip strength (kg/force) for 
the Intention-to-Treat Population showed a reduction, on average, in the Genotropin 
group and an increase, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
Table XXV: Change from Randomisation in Right Hand Grip Strength 
(kg/force) -  Placebo Group -  Intention to Treat Population
Visit 2 Visit 6
Number 16 16
Mean 30.907 31.069
Standard deviation 13.3492 13.5114
Median 30.150 29.000
Range (14.00, 55.67) (14.30, 58.30)
Table XXVI: Change from Randomisation in Right Hand Grip Strength 
(kg/force) -  Genotropin Group -  Intention to Treat Population
Visit 2 Visit 6
Number 16 15
Mean 28393 26.955
Standard deviation 10.9109 9.5181
Median 25.835 26.670
Range (14.30, 49.00) (11.30,44.67)
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The summary of change from randomisation in left biceps strength (Newtons) for the 
Intention-to-Treat Population showed a reduction, on average, in the Genotropin 
group and an increase, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
Table XXVII: Change from Randomisation in Electrodynamometer Readings of 
Left Biceps Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 16
Mean 151.209 158.970
Standard deviation 45.5152 55.5963
Median 145.000 138.165
Range (91.30, 229.00) (101.67, 281.67)
Table XXVIII: Change from Randomisation in Electrodynamometer Readings 
of Left Biceps Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 139.194 124.649
Standard deviation 40.9794 37.0365
Median 133.150 111.000
Range (84.00, 220.00) (89.60, 201.67)
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The summary of change from randomisation in right biceps strength (Newtons) for 
the Intention-to-Treat Population showed a reduction, on average, in both treatment 
groups after 14 weeks of treatment and at study termination.
Table XXIX: Change from Randomisation in Electrodynamometer Readings of 
Right Biceps Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 16
Mean 140.447 132.073
Standard deviation 36.8149 41.0567
Median 136.485 120.835
Range (88.77,209.30) (85.00, 223.30)
Table XXX: Change from Randomisation in Electrodynamometer Readings of 
Right Biceps Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population.
Visit 2 Visit 6
Number 16 15
Mean 125.906 118.052
Standard deviation 40.6520 35.0892
Median 116.485 105.670
Range (67.00,217.87) (66.30, 191.30)
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The summary of change from randomisation in left triceps strength (Newtons) for the 
Intention-to-Treat Population showed an increase, on average, in the Genotropin 
group and a reduction, on average, in the Placebo group after 14 weeks of treatment 
and at study termination.
Table XXXI: Change from Randomisation in Electrodynamometer Readings of 
Left Triceps Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 16
Mean 122.878 121.408
Standard deviation 45.8997 44.7504
Median 108.650 104.635
Range (70.67,257.30) (60.00, 204.00)
Table XXXII: Change from Randomisation in Electrodynamometer Readings of 
Left Triceps Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 110.289 116.145
Standard deviation 30.2298 41.5586
Median 112.835 107.600
Range (66.97,155.60) (69.30, 204.00)
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The summary of change from randomisation in right triceps strength (Newtons) for 
the Intention-to-Treat Population showed an increase, on average, in the Genotropin 
group and a reduction, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
Table XXXIII: Change from Randomisation in Electrodynamometer Readings 
of Right Triceps Strength (Newtons)-Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 107.211 103.447
Standard deviation 27.9344 31.9296
Median 101.800 95.335
Range (64.67, 156.67) (50.00,158.67)
Table XXXIV: Change from Randomisation in Electrodynamometer Readings 
of Right Triceps Strength (Newtons)-Genotropin group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 104.013 105.356
Standard deviation 27.9178 38.6114
Median 102.650 90.300
Range (66.67, 180.30) (66.30, 180.30)
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The summary of change from randomisation in left quadriceps strength (Newtons) for 
the Intention-to-Treat Population showed a reduction, on average, in both treatment 
groups after 14 weeks of treatment and an increase, on average, in the Genotropin 
group and a reduction, on average, in the Placebo group at study termination.
Table XXXV: Change from Randomisation in Electrodynamometer Readings of 
Left Quadriceps Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 74.537 64.190
Standard deviation 38.2967 25.0130
Median 65.335 64.600
Range (36.67,197.00) (36.67, 117.00)
Table XXXVI: Change from Randomisation in Electrodynamometer Readings 
of Left Quadriceps Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 64.098 57.121
Standard deviation 17.1659 13.2532
Median 61.670 59.00
Range (40.00, 105.23) (30.67, 78.00)
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The summary of change from randomisation in right quadriceps strength (Newtons) 
for the Intention-to-Treat Population showed a reduction, on average, in both 
treatment groups after 14 weeks of treatment and an increase, on average, in the 
Genotropin group and a reduction, on average, in the Placebo group at study 
termination.
Table XXXVII: Change from Randomisation in Electrodynamometer Readings 
of Right Quadriceps Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 73.458 62.057
Standard deviation 30.2789 23.8506
Median 65.450 52.670
Range (37.00, 161.00) (33.67, 113.00)
Table XXXVIII: Change from Randomisation in Electrodynamometer Readings 
of Right Quadriceps Strength (Newtons) -  Genotropin Group - Intention-to- 
Treat Population
Visit 2 Visit 6
Number 16 15
Mean 65.271 56.434
Standard deviation 14.5223 20.4497
Median 63.985 53.00
Range (47.73, 103.73) (28.00, 96.67)
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The summary of change from randomisation in left and right hamstring strength 
(Newtons) for the Intention-to-Treat Population showed an increase, on average, in 
the Genotropin group and a reduction, on average, in the Placebo group after 14 
weeks of treatment and at study termination.
Table XXXIX: Change from Randomisation in Electrodynamometer Readings 
of Right Hamstring Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 91.216 79.428
Standard deviation 52.6800 21.7039
Median 79.535 82.835
Range (33.67, 272.00) (20.30, 106.00)
Table XL: Change from Randomisation in Electrodynamometer Readings of 
Right Hamstring Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 75.926 76.683
Standard deviation 18.0513 24.3141
Median 74.335 73.670
Range (51.33, 110.67) (36.67, 123.30)
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Table XLI: Change from Randomisation in Electrodynamometer Readings of 
Left Hamstring Strength (Newtons) -  Placebo Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 90.085 84.890
Standard deviation 60.1128 24.0440
Median 78.150 87.485
Range (42.67, 307.67) (23.30,115.00)
Table XLH: Change from Randomisation in Electrodynamometer Readings of 
Left Hamstring Strength (Newtons) -  Genotropin Group - Intention-to-Treat 
Population
Visit 2 Visit 6
Number 16 15
Mean 74.094 75.871
Standard deviation 19.7847 17.6798
Median 70.665 74.300
Range (47.00,113.00) (42.60, 113.00)
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The summary of change from randomisation in 4 minute walking distance (m) for the 
Intention-to-Treat Population showed an increase, on average, in the Genotropin 
group and a reduction, on average, in the Placebo group after 14 weeks of treatment 
and an increase, on average, in both treatment groups at study termination.
Figure 6: Graph of four minute walk distances in the intention to treat
population
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The summary of change from randomisation in WOMAC pain score for the Intention- 
to-Treat Population showed an increase, on average, in the Genotropin group and no 
change, on average, in the Placebo group after 14 weeks of treatment and a reduction, 
on average, in both treatment groups at study termination.
The summary of change from randomisation in WOMAC stiffness score for the 
Intention-to-Treat Population showed a reduction, on average, in the Genotropin 
group and no change, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
The summary of change from randomisation in WOMAC physical function score for 
the Intention-to-Treat Population showed a reduction, on average, in both treatment 
groups after 14 weeks of treatment and at study termination
The summary of change from randomisation in AKS knee score for the Intention-to- 
Treat Population showed a reduction, on average, in both treatment groups after 14 
weeks of treatment and an increase, on average, in both treatment groups at study 
termination.
The summary of change from randomisation in AKS function score for the Intention- 
to-Treat Populations showed an increase, on average, in both treatment groups after 
14 weeks of treatment and at study termination
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Outcome of Surgery
Due to low event rates the median time to achievement of 90% active range of knee 
flexion or to achieve straight leg raise without lag (second of two consecutive days) 
was not calculable for the Genotropin group for both the Intention-to-Treat and the 
Per Protocol Populations. The median time to achievement of sit to stand with 
operated leg in front was two days for both the Genotropin and Placebo groups and 
for both the Intention-to-Treat and the Per Protocol Populations.
The number of in-patient days was comparable for both treatment groups, 9 days and 
8.5 days respectively for the Genotropin and Placebo groups for both the Intention-to- 
Treat and Per Protocol Populations.
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Quality of Life
The summary of change from randomisation in NHP physical activities score for the 
Intention-to-Treat Population shov^ed an increase, on average, in the Genotropin 
group and no change, on average, in the Placebo group after 14 weeks of treatment 
and an increase, on average, in both treatment groups at study termination.
The summary of change from randomisation in NHP pain score for the Intention-to- 
Treat Population showed an increase, on average, in the Genotropin group and no 
change, on average, in the Placebo group after 14 weeks of treatment and an increase, 
on average, in both treatment groups at study termination.
The summary of change from randomisation in NHP sleep score for the Intention-to- 
Treat Population showed no change, on average, in either treatment group after 14 
weeks of treatment and at study termination.
The summary of change from randomisation in NHP social isolation score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and at study termination.
The summary of change from randomisation in NHP energy level score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and an increase, on average, in the Genotropin 
group and no change, on average, in the Placebo group at study termination.
The summary of change from randomisation in NHP emotional reactions score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and at study termination.
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The summary of change from randomisation in AIMS mobility score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and at study termination.
The summary of change from randomisation in AIMS physical activities score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and a reduction, on average, in both treatment 
groups at study termination.
The summary of change from randomisation in AIMS dexterity score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and at study termination.
The summary of change from randomisation in AIMS household activity score for the 
Intention-to-Treat Population showed no change, on average, in either treatment 
group after 14 weeks of treatment and a reduction, on average, in the Genotropin 
group and no change, on average, in the Placebo group at study termination.
The summary of change from randomisation in AIMS social activity score for the 
Intention-to-Treat Population showed no change, on average, in the Genotropin group 
and a reduction, on average, in the Placebo group after 14 weeks of treatment and at 
study termination.
The summary of change from randomisation in AIMS activities of daily living score 
for the Intention-to-Treat Population showed no change, on average, in either 
treatment group after 14 weeks of treatment and at study termination.
The summary of change from randomisation in AIMS pain score for the Intention-to- 
Treat Population showed a reduction, on average, in the Genotropin group and an 
increase, on average, in the Placebo group after 14 weeks of treatment and a 
reduction, on average, in both treatment groups at study termination.
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The summary of change from randomisation in AIMS depression score for the 
Intention-to-Treat Population showed no change, on average, in the Genotropin group 
and a reduction, on average, in the Placebo group after 14 weeks of treatment and a 
reduction, on average, in both treatment groups at study termination.
The summary of change from randomisation in AIMS anxiety score for the Intention- 
to-Treat Population showed a reduction, on average, in the Genotropin group and no 
change, on average, in the Placebo group after 14 weeks of treatment and a reduction, 
on average, in both treatment groups at study termination.
The summary of change from randomisation in AIMS total health score for the 
Intention-to-Treat Population showed a reduction, on average, in the Genotropin 
group and an increase, on average, in the Placebo group after 14 weeks of treatment 
and a reduction, on average, in both treatment groups at study termination.
99
Laboratory Data
Summaries of change from randomisation in markers of growth hormone are 
summarised below. For the Genotropin group, on average, levels of IGF-1 increased 
while study medication was being up-titrated (i.e. until Week 6), but levels similar to 
those recorded at baseline were achieved by study termination. There was little 
change in the levels of IGFBP2 over the course of the trial for the genotropin group. 
Levels of IGFBP3 increased, on average, for the Genotropin group, until Week 14, 
and had returned to baseline values, on average, by study termination. Growth 
hormones levels remained steady, on average, over the course of the trial, for the 
Placebo group. No clinically significant laboratory abnormalities were found for 
either treatment group.
Figure 7: Graph of plasma IGF-1 levels during the study in the intention to treat 
population
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Figure 8: Graph of plasma IGFBP-2 levels during the study in the intention to
treat population
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Figure 9: Graph of plasma IGFBP-3 levels during the study in the intention to
treat population
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Vital Signs
It can be seen from Tables XLIII to XLIV that the mean diastolic blood pressure and 
mean systolic blood pressure, were similar at baseline in the Genotropin and Placebo 
groups and were similar to baseline at each time point during the trial. This was also 
true for temperature and pulse recordings.
Table XLIII: Mean diastolic blood pressure (mmHg) - Safety Population
Genotropin Placebo
Randomisation mean (Visit 2) 81.9 81.3
(SD 8.1) (SD 6.2)
Pre-Operative mean (Visit 6) 81.4 79.9
(SD 9.11) (SD 9.03)
Post-Operative mean (Visit 8) 79.3 78.5
(SD 7.56) (SD 7.70)
Table XLIV: Mean systolic blood pressure (mmHg) - Safety Population
Genotropin Placebo
Randomisation mean (Visit 2) 142.8 138.1
(SD 14.2) (SD 17.73)
Pre-Operative mean (Visit 6) 138.7 139.7
(SD 13.9) (SD 16.31)
Post-Operative mean (Visit 8) 136.5 135.7
(SD 9.65) (SD 11.23)
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Safety Evaluation
Adverse Events
Of the patients who were randomised and received at least one dose of trial 
medication, one subject in the placebo group reported a pre-treatment adverse event, 
diarrhoea and arthralgia. After randomisation, a total of 25 subjects reported adverse 
events (14 in the Genotropin group and 11 in the Placebo group respectively). The 
most frequently occurring adverse in either treatment group are shown in Table XLV. 
The most frequently occurring adverse events were urinary tract infections, joint 
swelling, peripheral swelling and paraesthesia.
Table XLV: Frequency of Treatment Emergent Adverse Events by Preferred 
term and Treatment Group -  Safety Population
Genotropin
(N=16)
Placebo
(N=16)
URINARY TRACT INFECTION 
NOS
2 (13%) 2 (13%)
JOINT SWELLING 3 (19%) 1(6%)
PERIPHERAL SWELLING 4 (25%) 0
PARAESTHESIA 4 (25%) 0
OEDEMA PERIPHERAL 3 (19%) 0
URINARY RETENTION 2 (13%) 1(6%)
CELLULITIS 1(6%) 1(6%)
LOWER RESPIRATORY 
TRACT INFECTION NOS
0 2 (13%)
NASOPHARYNGITIS 1 (6%) 1(6%)
CARPAL TUNNEL SYNDROME 2 (13%) 0
COUGH 0 2 (13%)
ECXZEMANOS 0 2(13%)
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Urinary tract infection was reported in two subjects in the genotropin group and two 
subjects in the placebo group; all incidences were mild in severity and considered to 
be unrelated to study medication. Joint swelling was reported in three subjects in the 
genotropin group and one subject in the placebo group; all incidences were mild in 
severity and considered to be related to study medication and as a consequence, dose 
of study medication was down titrated. Peripheral swelling was reported in four 
subjects in the genotropin group; three incidences were considered to be mild and one 
to be moderate in severity, all were considered to be related to study medication, and 
the study medication was withdrawn temporarily or down titrated as a consequence. 
Paraesthesia was reported in four subjects in the genotropin group; two incidences 
were considered to be moderate and two to be mild in severity, all were considered to 
be related to study medication, and the study medication was withdrawn temporarily 
or down titrated as a consequence.
Two treatment emergent adverse events were considered serious, one in each 
treatment group. A subject in the genotropin group had an event of paraesthesia 
(slight tingling in left arm/hand -  intermittent) which was mild in intensity, and 
considered to be related to study medication. The symptoms became less severe on 
down titration of study medication. A subject in the placebo group suffered a 
pulmonary embolism. This adverse event and another of urinary retention caused the 
study medication to be permanently withdrawn for this subject.
Severity, relationship to and action taken with study medication are presented in 
Table XLVI.
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Table XLVI: Severity and Relationship to Trial Medication and Action with 
Study Medication of Treatment Emergent Adverse Events per Treatment 
Group- Safety Population
Genotropin
(N=16)
Placebo
(N=16)
Severity
Mild 12 (75%) 11 (69%)
Moderate 5(31%) 2 (13%)
Severe 1(6%) 1 (6%)
Related to Study Medication 11 (69%) 4(25%0
Action with Study Medication 12 (75%) 2 (13%)
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Chapter 5 
DISCUSSION
The aim of this study was to assess whether growth hormone treatment prior to 
elective knee surgery could:
(i) have a biological effect
(ii) effect body composition favourably with an increase in muscle mass pre- 
operatively and prevent loss of muscle mass post-operatively.
(iii) Improve the surgical outcome
- attainment of functional goals pre discharge.
- length of stay in hospital
- improve functional outcome
(iv) improve patient quality of life
- globally 
disease specific
(v) was a safe treatment
I would like to discuss each in turn and put them in context of other reported studies.
(I) Have a biological effect.
Growth hormone treatment caused IGF-1 and BP-3 circulating levels to increase 
compared to placebo. The GH treatment caused a large rise despite the age and frailty 
of some of the patients. The dose of GH given was higher than the usual GH 
replacement given to adult GHD patients (Carroll, 1998) and thus the relatively high 
IGF-1 levels attained were not unexpected. The rise was comparable to the study of
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Weissberger, 2003 who used a similar protocol to investigate the pre-op effect of 
growth hormone in patients undergoing hip replacement.
The IGF BP-3 rise was also expected and can be explained in terms of the GH 
regulation of BP-3 production and circulating levels. Plasma IGFBP-3 concentrations 
are positively regulated by GH. The IGF-1/IGFBP3 complex circulates in the vascular 
system with a half-life of 12-15 hours, the half life of free IGF-1 being less than 10 
minutes. There was little change in the levels of IGFBP2 over the course of the trial 
for the genotropin group. To date six binding proteins have been fully characterised 
but recent evidence suggests that there may be as many as 10 binding proteins 
(Baxter, 2000). The functions of the IGFBPs are to act as transport proteins, to “store” 
IGF-I within the circulation thereby prolonging the half-lives and regulate the 
metabolic clearance of IGF-I, to provide a means of tissue and cell-type-specific 
localisation, and to modulate interaction with the IGF-I receptor (Jones, 1995). 
IGFBP3 is produced by the liver and is the most abdundunt of the IGFBPs in adults, 
accounting for 95% of the total circulating IGFBPs. The rise in IGF-1 and IGFBP3 
confirm the biological effect of growth hormone in our treatment group.
Regulation of IGFBP gene transcription is complex and tissue specific. A number of 
hormones, including oestrogens, glucocorticoids, parathyroid hormone, FSH, GH, 
thyroid hormone, insulin, vitamin D, and cortisol, and growth factors have been found 
to regulate the expression of IGFBPs (Kelly KM, 1996). Nutritional status also affects 
the level of IGFBP-2 in the serum. Fasting increases its level substantially; however, 
this response occurs slowly. A role for insulin in regulating the level of IGFBP-2 in 
serum has been suggested by animal experiments but has not been seen in humans 
(Jones, 1995). Energy intake, body mass index ([weight in kg]/[height in m]<2>), and 
physical activity all appear to affect blood levels of IGFs and IGFBPs. However, the 
intimate relationship among these variables makes disentanglement of their 
independent effects difficult and perhaps begins to explain the lack of response of 
IGFBP-2 in our study group.
(II) Body composition
GH treatment given to adult GHD patients causes a significant increase in lean body 
mass and a reduction in fat mass. The big question going into this current study was
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whether GH treatment, albeit at supraphysiological doses could improve lean body 
mass in normal elderly patients with severe knee osteoarthritis. Another question was 
whether the quadriceps and leg muscles in general (leg lean body mass) could 
increase in response to GH treatment even if the patient had a relative disuse atrophy 
because of the severe osteoarthritis of the knee. The final question was whether there 
could be any differences between the diseased and non-diseased legs in terms of 
response.
The results of our study show unequivocally that total lean body mass increases 
significantly. The increase of approximately 2 kg is slightly less than that seen in 
studies of adults with growth hormone deficiency (Carroll, 1998) but comparable to 
the study of Weissberger (2000) studying patients undergoing hip replacement and 
early studies such as Rudman (1990) Kaiser (1991) and Papadakis (1996).
Aging is associated with a fall in GH secretion and physiological changes similar to 
those observed in younger adults who have organic GH deficiency. The beneficial 
effects of GH replacement in growth hormone deficiency has led to much optimism as 
to the therapeutic advantages of GH in the elderly with respect to body composition 
and strength and was a major component of the rationale for this study. Rudman used 
growth hormone to increase the serum IGF-1 of healthy men to a value observed in 
adults in their twenties. Over a 6 month period GH therapy resulted in an increase in 
lean mass, a decrease in fat mass and a significant rise in bone mineral density. Lean 
body mass rose by 8.8% and lumbar vertebral density by 1.6%. The magnitude of the 
changes produced was equivalent to a reversal of the age-related changes by 10-20 
years. Despite the significant gains in muscle mass actual muscle strength did not 
improve (Taafe, 1994). Similar changes in body composition are seen in other studies. 
Ten malnourished elderly patients aged 64-99 years with body weight 20% or more 
below average were given rhGH as part of a placebo controlled study, (Kaiser, 1991). 
Treatment produced a rise in circulating IGF-1 and weight gain of 2.2Kg in contrast 
to a weight loss in the control group. There was a significant association between 
IGF-1 level and weight gain. A significant increase in nitrogen retention occurred, 
suggesting that the weight gain was at least partly due to lean tissue. Cohn, 1993 
showed that there was a clear dosage effect, with those receiving treatment which
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produced an IGF-1 level between 0.5 and l.OU/ml having a greater gain in lean body 
mass and fewer side effects than those with a higher IGF-1 level.
The regional differences in the leg quantified by CT as well as dexa, showed 
equivalent results with leg muscle (lean body mass) increasing. Thus despite the low 
amount of work that was being performed by the muscles because of the severe 
osteoarthritis, the muscle bulk still increased. It is very striking in this study that the 
lean mass gained by growth hormone treatment pre-operatively, appears to be lost 
preferentially post operatively. Thus, the increase in lean body mass recorded in this 
study may have been artefactual, i.e. fluid. Against this is the CT data which shows 
unequivocally the muscle tissue increased in size, but does not preclude fluid 
retention being within the muscle tissue itself. An alternative explanation could be 
that any lean body mass that has accrued during the growth hormone treatment, was 
more susceptible to catabolic processes that occur with surgery. This finding is 
however in keeping with the results of a number of short term studies in patients 
following major surgery or trauma or suffering critical illness (Wilmore, 1991; 
Desai&Jacobs, 1996; Schambelan, 1996; Kissmeyer-Nielsen, 1999; Garmin, 2000). 
These studies typically used larger doses 0.2-0.4 U/Kg/day to overcome the resistance 
to the action of GH and consequent impairment of IGF-1 that is characteristic of this 
setting (Ross, 1991). Nutritional support was not specifically employed in this study 
and might be required in combination with GH treatment to minimize the catabolic 
response to surgery (Wilmore, 1991) particularly when lower doses of growth 
hormone are used. Weissberger et al showed a comparable gain in lean body mass in 
the study investigating GH treatment prior to elective hip replacement, but they 
recorded no net loss of muscle in the growth hormone treated patients post operatively 
compared with a 10% loss in the placebo treated patients. That study used doses of 
0.04U/Kg/day which was comparable to our study, as the majority patients received 
0.05 U/Kg/day; further dose titration was not possible due to adverse events. The 
Weissberger group doubled the dose in the first two weeks post-operatively and it is 
possible that this may have off set the catabolic response to surgery. IGF-1 levels 
were comparable between the two studies.
(Ill) Improved surgical outcomes.
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The growth hormone treatment although causing an increase in lean body mass did 
not improve muscle function pre-operatively and did not improve muscle function 
post-operatively. No discernable difference between placebo and growth hormone 
were seen in functional assessments of the arm (not affected by knee osteoarthritis). 
Whilst in hospital those given growth hormone did not attain pre-set functional goals 
following surgery any faster than those given placebo. The length of stay was no 
different. Despite following a detailed integrated care pathway to ensure similar 
treatments and physiotherapy post operatively, the clinician availability to set 
discharge (consultant ward round) always played the maximum rate limiting step for 
discharge. The four minute walk showed no significant changes between the two 
groups but there was a trend in favour of the treatment group with an increase, on 
average, in the Genotropin group and a reduction, on average, in the Placebo group 
after 14 weeks of treatment and an increase, on average, in both treatment groups at 
study termination. Papadakis, 1996 showed no change in muscle function following 
growth hormone treatment for six months using a dose similar to our dosing in 
healthy elderly men with low IGF-1 levels. In adult growth hormone deficiency due to 
pituitary disease and/or surgery where the effects of GH on muscle strength have been 
investigated more intensively, results have also been inconclusive, with either no 
change after relatively short treatment (up to 6 months) or a less than expected 
positive effect for muscle mass (Jorgensen, 1989; Cuneo, 1991). There is also 
significant imprecision in strength testing methods including operator technique and 
patient co-operation. Reproducable limb positioning is difficult in the elderly and 
often osteoarthritis in other joints other than the knee to be operated on made 
assessments difficult. The WOMAC score for pain, stiffness and function showed no 
significant differences between the two groups. The AKS scores which assessed pain, 
assessment of joint function and global function of the patient found no sigmficant 
differences between the two treatment groups. These findings are in keeping with 
those of Weissberger, 2003 who also found no obvious effect of growth hormone on 
the response to hip replacement surgery.
(IV) Quality of Life
Quality of Life was measured with a global well validated score (the Nottingham 
Health Profile). This was used as previous studies have employed this tool to assess
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the impact of growth hormone replacement in adult growth hormone deficient 
patients. In that patient group, vitality, energy, emotional and social isolation scores 
all improved but was accompanied by a deterioration in the pain score. The latter was 
explained by the side effects of peripheral oedema and myalgia/arthralgia.
In the present study the pain score also changed adversely with growth hormone 
initially but the over riding and dominant pain was due to the osteoarthritis itself. The 
disease specific questionnaires showed changes that would be expected from patients 
severely affected by their arthritis that is improved with the joint replacement by the 
end of the study. The WOMAC score clearly demonstrates this trend. The summary 
of change in AIMS pain score for the showed a reduction, on average, in the 
Genotropin group and an increase, on average, in the Placebo group after 14 weeks of 
treatment and a reduction, on average, in both treatment groups at the study 
termination.
The AIMS health profile (total score) showed a beneficial trend in the treatment 
group, in keeping with the quality of life changes that are seen in the treatment of 
growth hormone deficient patients.
(V) Safety
Two serious adverse events were recorded, one in each treatment group. In the growth 
hormone group parasthesia was recorded and was mild in intensity, and considered to 
be related to study medication. Symptoms became less severe on down titration of 
study medication. In the placebo group pulmonary embolism was recorded and was, 
considered to be related to study medication and caused the study medication to be 
permanently withdrawn for that subject.
The total number of subjects with treatment-emergent adverse events was 14 (88%) in 
the growth hormone group and 11 (69%) in the placebo group. The most frequently 
occurring adverse events were urinary tract infections, joint swelling, peripheral 
swelling and paraesthesia.
Urinary tract infection was reported in two subjects in the growth hormone group and 
two subjects in the placebo group; all incidences were mild in severity and considered 
to be unrelated to study medication. Joint swelling was reported in three subjects in 
the growth hormone group and one subject in the placebo group; all incidences were 
mild in severity and considered to be related to study medication and had dose of 
study medication down titrated as a consequence. Peripheral swelling was reported in
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four subjects in the growth hormone group; three incidences were considered to be 
mild and one to be moderate in severity, all were considered to be related to study 
medication, and the dose of study medication was withdrawn temporarily or down 
titrated as a consequence. Paraesthesia was reported in four subjects in the growth 
hormone group; two incidences were considered to be moderate and two to be mild in 
severity, all were considered to be related to study medication, and the dose of study 
medication was withdrawn temporarily or down titrated as a consequence.
FINAL CONCLUSIONS AND LIMITATIONS
This study has shown that it is possible to induce an increase in total and regional lean 
body mass or muscle mass in normal elderly patients with severe osteoarthritis. This 
increase in muscle mass occurred in the legs and quadriceps despite the suffering 
from a relative disuse of atrophy secondary to the severe osteoarthritis of the knee. 
This study failed to show an objective improvement in response to surgery, length of 
stay in hospital or functional outcome. It is possible the study was under powered to 
show a difference of other events, e.g. problems following surgery influence the 
results more greatly than the subtle effect of growth hormone.
It is of considerable interest that the physiotherapists were largely able to guess who 
was on growth hormone by their attitude and response once the codes were broken at 
the end of the study. Functional muscle assessments are notoriously insensitive and it 
is possible that the measurements were too crude to pick up subtle effects of growth 
hormone. The model has worked to show that it is possible to improve lean body 
mass and muscle mass in elderly patients with osteoarthritis. The patient group with 
possibly the most to gain by such an intervention are those undergoing knee 
replacement for rheumatoid arthritis. This group are usually younger and have a 
lower muscle mass and more severe disease atrophy. They also have usually been 
exposed to large doses of steroids that have a profound catabolic effect. There is 
emerging evidence to suggest that adult GHD patients who previously had Cushing’s 
prior to developing hyperpituitarism, respond the best to growth hormone 
replacement. Thus the next study should be to study rheumatoid arthritis patients but 
in sufficient number to improve the power of the study.
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